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A B S T R A C T
Serotonin (5-hydroxytryptamine, 5-HT) is a major neurotransmitter
in the brain biosynthesis of which is initiated by tryptophan hydroxy-
lase 2 (TPH2). Polymorphisms in the TPH2 gene are suggested as risk
factors associated with depression and anxiety in humans. Further-
more, the most frequently prescribed antidepressants and anxiolytics
target the serotonergic system. However, the question whether a com-
plete ablation or partial reduction in brain serotonin leads to the de-
velopmental, neurochemical, or psychological abnormalities remains
unresolved.
In this study, I took advantage of mouse lines with various degree of
decrease in TPH2 activity in order to dissect the impact of 5-HT loss
on development, brain neurochemistry and behavior.
Using Tph2-deficient mice I showed that central serotonin is essen-
tial for normal postnatal, but not prenatal development. Growth re-
tardation of Tph2-/- mice was not a result of a disruption of the
hypothalamo-pituitary-adrenal axis, metabolic abnormalities, or im-
paired thermoregulation, but could result from reduced ultrasonic
vocalization.
I tested Tph2-/- mice along with other newly generated mouse mod-
els with partial TPH2 reduction, and showed that 20% reduction in
central serotonin is not enough to cause changes in anxiety- and
depression-like behaviors most likely due to compensatory mecha-
nisms including reduced serotonin metabolism and increased 5-HT1A
receptor sensitivity.
However, complete loss of central serotonin leads to a depression-
like phenotype, reduced anxiety-like behavior, and exaggerated ag-
gression, but no differences in activity, olfaction, memory, and adult
neurogenesis.
Fluoxetine treatment of Tph2-/- mice revealed serotonin-independent
action of this antidepressant on anxiety- and depression-like behavior.
Furthermore, fluoxetine drastically reduced the brain 5-HT content
in mice with low TPH2 activity indicating that TPH2 activity may
determine the efficiency of antidepressants targeting the serotonergic
system.
Keywords: Tryptophan hydroxylase, Serotonin, Development, Be-
havior, Fluoxetine
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Z U S A M M E N FA S S U N G
Serotonin (5-Hydroxytryptamin, 5-HT) ist ein wichtiger Neurotrans-
mitter im Zentralnervensystem (ZNS). Seine Biosynthese erfolgt unter
Beteiligung des Enzyms Tryptophanhydroxylase 2 (TPH2). Polymor-
phismen im TPH2 Gen beim Menschen sind Risikofaktoren bei der
Entstehung von Depressionen und Angstverhalten. Die gängigsten
Antidepressiva und Anxiolytika wirken auf das Serotonin System.
Unklar ist, ob das komplette oder teilweise Fehlen von Serotonin im
Gehirn zu Entwicklungsstörungen und neurochemischen oder psy-
chologischen Veränderungen führt.
In dieser Arbeit werden Mauslinien mit unterschiedlichen TPH2 Akti-
vitäten im ZNS verglichen und der Einfluss verringerter 5-HT Konzen-
trationen auf Entwicklung und Verhalten der Tiere untersucht. Zen-
trales Serotonin ist nur für die postnatale Entwicklung notwendig.
Das verzögerte Wachstum von Tph2-/- Tieren ist nicht auf eine Störung
der Hypothalamus-Hypophysen-Nebennieren-Achse oder auf metabo-
lische Veränderungen zurückzuführen, sondern kann aus verringerter
Vokalisation im Ultraschallbereich resultieren. Tph2-/- Mäuse wurden
mit generierten Mausmodellen mit niedriger TPH2 Aktivität vergle-
ichen. Die Ergebnisse zeigen, dass 20% weniger zentrales Serotonin
nicht ausreichen, um Depression oder Angst-Verhalten herbeizuführen.
Möglicherweise greifen kompensatorische Mechanismen wie ein ver-
ringerter Serotoninmetabolismus oder eine gesteigerte 5-HT1A-Rezep-
torsensitivität. Der komplette Verlust von Serotonin im Gehirn führt
zu einem starken depressiven und weniger ängstlich Verhalten, mit
erhöhter Aggression - ohne Veränderung in Aktivität, Geruchsinn,
Gedächnis und adulter Neurogenese. Fluoxetine Behandlung von Tph2-
defizienten Mäusen zeigte einen Serotonin-unabhängigen Effekt dieses
Antodepressivums auf Angst-Verhalten und Depression. Fluoxetine
reduzieren den Serotoningehalt im Gehirn von Mäusen mit geringen
TPH2-Aktivität, was zeigt, dass TPH-Aktivität die Effizienz von Sero-
tonin beeinflussenAntidepressiva bestimmen.
Schlagwörter: Tryptophan hydroxylase, Serotonin, Entwicklung, Ver-
halten, Fluoxetine
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1
I N T R O D U C T I O N
1.1 serotonin - history, metabolism , and mechanisms of
action
1.1.1 Discovery of serotonin
Serotonin (5-hydroxytryptamine, 5-HT) was discovered in the mid-
dle of the 20th century. Scientists from the Page group were the first
to isolate and identify the vasoconstrictive substance from the serum
which was released while the blood was clotting [152]. Due to the
source, serum, and its action, tonic, this substance encountered the
name ’serotonin’ [152]. At the same time Erspamer was working on
a muscle dilating substance, which he named ’enteramine’ [184]. At
the end, he found out that ’serotonin’ and ’enteramine’ are the same
factors. A couple of years later, in 1953, Twarog and Page discovered
serotonin in the central nervous system [199]. Further serotonin crea-
tinine sulfate was synthesised, bursting the development of new ana-
lytical methods to study serotonin metabolism in vivo and in vitro. Bet-
ween 1953 and 1970 the processes of serotonin synthesis and degra-
dation were clarified [184]. Moreover, during this time many impor-
tant drugs interacting with the serotonergic system were discovered.
Among them are reserpine (further known as vesicular monoamine
transporter (VMAT) inhibitor), monoamine oxidase (MAO) inhibitors
(pargyline, phenelzine, tranylcypromine, isocarboxazid), lysergic acid
diethylamine (LSD), aromatic amino acid decarboxylase (AADC) in-
hibitor (carbidopa), tryptophan hydroxylase (TPH) inhibitor (para-
chlorphenylalanine), and tricyclic antidepressants (imipramine, de-
sipramine, amitriptyline, nortriptyline, protriptyline) [184].
1.1.2 TPH1 and TPH2: serotonin synthesising enzymes
The biosynthesis of serotonin is a two-step process. On the first step
the essential amino acid L-tryptophan (Trp) is metabolized to 5-hydro-
xytryptophan (5-HTP) by the rate-limiting enzyme TPH Figure 1.
Next, 5-HTP is decarboxylated to 5-HT by the AADC Figure 1. This
enzyme is involved as well in the synthesis of dopamine from l-3,4-
dihydroxyphenylalanine (L-DOPA) [91], tryptamine from tyrosine [102]
or tryptophan [57], and its distribution and functions are not restricted
just to the serotonergic system. Thus, the whole process of serotonin
synthesis in the brain is limited by two factors: availability of its sub-
strate, Trp, and activity of the TPH enzyme.
3
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Tryptophan
(Trp)
5-Hydroxytryptophan
(5-HTP)
TPH
PCPA
5-Hydroxytryptamine
(5-HT, Serotonin)
AADC
MAO SNAT
N-Acetylserotonin
Melatonin
5-Hydroxyindole 
acetaldehyde
5-Hydroxyindole
acetic acid (HIAA)
HIOMTADH
NSD
Figure 1: Serotonin synthesis and metabolism. TPH: tryptophan hy-
droxylase, AADC: aromatic amino acid decarboxylase, PCPA:
parachlorophenylalanine (p-chlorophenylalanine), NSD: 3-
hydroxybenzylhydrazine dihydrochloride, SNAT: serotonin
N-acetyltransferase, HIOMT: hydroxy-indole-O-methyl trans-
ferase, MAO: monoamine oxidase, ADH - alcohol dehydrogenase,
modified from [136].
TPH belongs to the superfamily of aromatic amino acid hydroxy-
lases that also includes tyrosine hydroxylase (TH) and phenylalanine
hydroxylase (PAH). These are iron (Fe2+)- and tetrahydrobiopterin
(BH4)-dependent monooxygenases with substantial structural simi-
larities in their catalytic mechanism [65]. All aromatic amino acid
hydroxylases are composed of 3 functional domains, a regulatory
N-terminal domain, a catalytic domain and a C-terminal oligomeri-
zation domain [208, 65].
Since discovery of the serotonin synthesis pathway, it was supposed
that in vertebrates only one form of TPH enzyme exists [105]. Howe-
ver, in 2003 the existence of a second isoform, Tph2, was unravelled by
genetical ablation of the only known Tph gene [214, 213]. This spec-
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tacular discovery gave new opportunities for studying the functions
of two independent serotonin systems — central, driven by Tph2, and
peripheral, driven by Tph1. Follow-up studies of mRNA and protein
levels in rodents and human tissues confirmed TPH2 to be the central
isoform, which is predominantly expressed in the neurons of Raphe
nuclei in the brainstem [78, 155, 213], and in peripheral myenteric
neurons in the gut [147, 43], but is absent in peripheral organs like
lung, heart, kidney, or liver [173, 231]. On the other hand, TPH1 is
mainly expressed in the enterochromaffin cells of the gut and also in
the pineal gland, where it produces 5-HT serving as a precursor for
melatonin synthesis [185, 213] Figure 1.
1.1.3 Serotonin metabolism
In the brain, there are two main serotonin-degradation pathways. In
serotonergic neurons, serotonin can be degraded to 5-hydroxyindolea-
cetic acid (5-HIAA) by one of the forms of MAO — MAO-A Figure 1.
MAO-A also metabolises norepinephrine [101]. Furthermore, another
form of MAO, MAO-B, metabolises benzamidine [117]. Both enzymes
are able to metabolize tyramine and dopamine [101]. Distribution of
both isoforms in the brain reflects its substrate specificity [39]. In pitui-
tary gland, retina and epiphysis serotonin serves as precursor in the
synthesis of melatonin. First, it is degradated to N-acetylserotonin by
5-HT-N-acetyl-transferase (SNAT). Than the intermediate substrate
get processed to melatonin by N-acetyl-5-HT-O-methyl-transferase
(HIOMT) [41] Figure 1.
1.1.4 Formation of serotonergic neurons
Neurons producing serotonin are located in a restricted region of the
brainstem. They are organized in 9 groups of cells that form two clus-
ters according to their location — B1-B5 (corresponding to the raphe
pallidus, magnus, obscurus, and pontis) and B6-B9 (corresponding to
the dorsal and median raphe nuclei) [212, 121, 47]. The percentage of
5-HT to all neurons in the brain is only 0.0002%. However, extensive
innervations of different brain regions and spinal cord allow to regu-
late a lot of essential physiological functions [121]. In mice, serotoner-
gic neurons start to develop from embryonic day 10 to 12, whereas in
primates it happens during the first month of gestation [118]. Howe-
ver, the full maturation of 5-HT neurons in rodents occurs only after
birth [121].
Several molecular factors essential for the formation of the 5-HT neu-
rons were identified. Among them Lmx1b and Pet1 are two most es-
sential transcription factors for the last stage of serotonergic neuron
differentiation. Lmx1b is a LIM homeodomain-containing factor. The
name of the family, LIM, was given by the initials of the three pro-
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teins Linl-1, Isl-1, Mec-3, in which this homeodomain was first dis-
covered. Its expression is not restricted to only serotonergic neurons,
but was found as well in the subthalamic nucleus, substantia nigra,
pons, and the dorsal part of the spinal cord [10]. In the mouse hind-
brain, Lmx1b expression starts at E10.5 and persists during adult life
[55, 188]. Lmx1b controls the expression of its downstream gene Pet1.
The expression of the ETS (E26 transformation-specific) domain con-
taining transcription factor Pet1 (pheochromocytoma) was found pri-
marily in neuronal tissue [70], starting at E12.75 in rat [88] and at E11
in mouse [162]. In the brain, Pet1 expression is restricted to the raphe
nuclei and specifically to the serotonergic neurons [88]. Moreover, a
conserved cis-binding site for Pet1 was found in several genes exp-
ressed exclusively in serotonergic neurons such as Sert and 5-HT1A
receptor [88].
Figure 2: Serotonergic synaptic terminal. Abbreviations: 5-HT: serotonin,
5-HTP: 5-hydroxytryptophan, Tph2: tryptophan hydroxylase 2,
AADC: aromatic amino acid decarboxylase, Sert: 5-HT transporter,
MAO: monoamine oxidase, 5-HIAA: 5-hydroxyindoleacetic acid,
Vmat2: vesicular monoamine transporter 2 [62].
1.1.5 Serotonergic neurotransmission
After synthesis VMAT-mediated serotonin packaging into vesicles oc-
curs Figure 2. Similar to the serotonin-synthesising enzyme, VMAT
exists in two forms: central — VMAT2, and peripheral — VMAT1
[58, 59]. VMAT2 is expressed in all monoaminergic neurons, thus its
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expression is not restricted only to 5-HT neurons.
Once 5-HT is packed into the vesicles it is released into the synaptic
cleft via exocytosis upon cell stimulation Figure 2. There it can imple-
ment its action on the postsynaptic cell via specific 5-HT receptors. By
now, 16 different serotonin receptors have been described that are di-
vided into 7 families by homology, signal transduction pathways, and
sensitivity to pharmacological modulations [16, 129]. The most inte-
resting receptor for this study is the 5-HT1A receptor. It is expressed
either as postsynaptic receptor in the hippocampus, cortical regions,
septum, amygdala, and hypothalamus or as presynaptic receptor in
dorsal and median raphe nuclei [114]. 5-HT1A receptor is negatively
coupled through G-proteins (αi) to adenylate cyclase. Thus, due to
the negative feedback mechanisms activation of presynaptic recep-
tors causes a decrease in firing of the presynaptic cell, that in term
causes a decrease of serotonin release into the synaptic cleft [2, 3, 24].
Stimulation of postsynaptic 5-HT1A receptors causes decrease in fi-
ring rates of the neurons on which they are located [24, 189, 193].
Once serotonin completes its action it is reuptaken back into the
presynaptic cell with help of the selective serotonin transporter (SERT)
Figure 2. Besides the expression of Sert in 5-HT neurons, it was found
as well in non-serotonergic cells in different structures of the telen-
cephalon, diencephalon, and brain stem [19, 117]. Pharmacological
inhibition or blockage of SERT leads to the prolongation of serotonin
actions, and is largely used in the treatment of psychiatric disorders
[207].
1.2 central serotonin and TPH2 in humans
1.2.1 Mutations in TPH2 and its contribution to psychiatric states in hu-
mans
It has been postulated that reduction in brain serotonin leads to inc-
reased depressive and aggressive behaviors. Discovery of a second,
brain specific TPH isoform, TPH2, triggered genetic studies on poly-
morphisms in the TPH2 gene to assess the implications of central
serotonin in the development of neuropsychiatric disorders. Several
single nucleotide polymorphisms (SNP) in the TPH2 gene have been
found to be associated with depression [82, 198, 203, 225, 229, 230],
suicidal behavior [36, 82, 85, 84, 127, 169, 229, 232] and bipolar disor-
der [36, 85, 84, 122, 127, 169, 203, 232]. On the other hand a number of
publications documented no association between TPH2 SNPs and ma-
jor depression or suicide [52, 71, 73, 98, 134, 142]. These inconsistent
results may reflect the heterogeneous nature of neuropsychiatric di-
seases and populations on one side, and methodological differences,
sample size and statistical power on the other.
In particular, the non-synonymous SNP (G1463A) published by Zhang
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et al. (2005) seemed to be a promising step towards identifying a link
between TPH2 and depressive disorders [224]. The resulting missense
mutation in the TPH2 protein (R441H) that they found in an elderly
cohort of unipolar depressed patients showed an 80% decrease in 5-
HT production in PC12 cells. The fact that the mutation is located
within the part of the oligomerization domain that has previously
been shown to be pivotal for TPH2 activity [195] together with the
description of a corresponding severe pathogenic mutation in PAH
(R408W) led to the expectation that the first loss of function muta-
tion in human TPH2 had been identified [223]. However, this poly-
morphism could not be found in any other study [22, 23, 53, 71, 74,
90, 158, 202, 228]. Thus, it is probably a rare mutation within a very
unique cohort with unipolar depression. Interestingly, the same SNP
in TPH2 was later found as a result of RNA-editing in postmortem
brain tissue of humans suffering from psychiatric disorders (drug
abuse, schizophrenia, suicide) [75].
As the coding sequence of TPH2 represents less than 2% of the gene,
coding sequence variants are expected to be rather rare [171]. There-
fore most of the so far known TPH2 SNPs are located in introns and
promoter regions. Although they are not likely to be of functional
importance, they could affect gene expression on the transcriptional
level e.g. via mRNA stability or splicing processes [25]. The T allele
of the TPH2 promotor polymorphism rs4570625 (-703G/T) has been
shown to be involved in increased prefrontal brain activity [167], an-
xiety related personality disorders [79] and amygdala reactivity [29,
33]. Therefore it might have an impact on heightened stress responsi-
vity and anxiety due to alterations in TPH2 expression [191]. Another
intronic TPH2 SNP has been reported to reduce promoter activity by
reduced binding of the transcription factor POU3F2 [122, 178]. Evi-
dence for an inhibitory effect of the TPH2 5’-UTR on gene expression
has been derived from studies on common polymorphisms and hap-
lotypes in this region [35]. From the so far known TPH2 missense
mutations 4 have been reported in patients with clinical symptoms
[137]. Nevertheless, there is still a great demand for functional and
clinical data to define the role of TPH2 polymorphisms in particular
phenotypes of depressive disorders [81]. Furthermore, inconsistent re-
sults have been published for other types of affective disorders. Some
studies showed TPH2 polymorphisms to be related to schizophrenia,
obsessive-compulsive disorder (OCD), attention-deficit hyperactivity
disorder (ADHD), and autism or panic disorder [40, 106, 141, 182,
211], while others did not observe any association [51, 141]. Con-
cordant response rates from several studies with relatives suggest
that antidepressant treatment response is also an inheritable trait pos-
sibly influenced by TPH2 polymorphisms [67, 150]. However, apart
from some studies showing a significant link between a TPH2 SNP
haplotype and selective serotonin reuptake inhibitor (SSRI) response
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[159, 198, 200] there are again others claiming no association between
this trait and TPH2 SNPs in various ethnic populations [71, 98, 158].
1.2.2 Mouse as a model for human disorders
Studies in genetically modified laboratory animals have an impor-
tant impact on our understanding of psychiatric disorders and on tes-
ting new pharmacological tools that could be further used in trea-
ting these diseases in humans. Especially valuable in this respect is
the mouse — a species in which human mutations can be easily mi-
micked by genetic modification of its genome. However, the useful-
ness and validity of mouse models in evaluation of human emotional
behavior is always an issue. As there are differences in brain anatomy
and capacity for processing complex psychological concepts between
humans and mice, it is impossible to model certain aspects of di-
sease symptoms in mice. For depression, for example, it is impos-
sible to show behaviors such as low self-esteem, suicidal ideation or
"fear of going crazy". On the other hand, among mammals the brains
have a common structural organization, similar circuits connecting
these structures, as well as conserved physiological and behavior res-
ponses. Therefore, to a certain extent mouse can be used as a model
for understanding human behavior and disease, but it always has to
be done with caution [45].
However, mouse models with complete gene inactivation are not the
only source for studying the influence of certain genes on emotional
behavior. In humans a more likely source of phenotypic difference is
the accumulation of certain SNPs over generations. Due to extensive
inbreeding laboratory mouse strains are good models to study the ef-
fect of SNPs on physiological processes and behavioral phenotypes.
1.3 hyposerotonergic animal models
1.3.1 Tph2-deficient mice
Since the discovery of Tph2 mouse models genetically depleted of
brain serotonin-synthesising enzyme were created by several labora-
tories [80, 78, 110, 125, 138, 196, 219]. In Table 1 the data obtained
from various studies about the degree of central serotonin reduction,
serotonin neuron formation and branching, and changes in other neu-
rotransmitter systems in Tph2-deficient mice are summarized. Alto-
gether, dramatic reduction in central 5-HT and no gross abnormali-
ties in 5-HT neuron formation are the main characteristics of mouse
models constitutively lacking Tph2 [4, 80, 78, 110, 138, 176, 219]. Ho-
wever, reports about the state of other neurotransmitter systems in
mice lacking Tph2 are controversial, and indicate either no or mi-
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Genetic 
model
Type/ 
deficiency
Back-
ground Brain 5-HT levels 
5-HT+/Tph2+ 
neurons (IHC)
5-HT neuronal 
markers/ 
properties of 5-
HT neurons
Tph2 
expression Projection of 5-HT neurons
Other neurotransmitter 
systems/factors
Refe-
rence
Tph2
-/- constitutive, 
complete
C57Bl/6, 
6th 
generation
complete absence of 
5-HT in the raphe 
nuclei
normal SERT 
expression at 
some, dendrites 
and terminals of 5-
HT neurons
no difference in SERT 
expression in different brain 
regions including hippocampus
[80]
Tph2
-/- constitutive, 
complete
mixed 
reduction by more than 
92% in C, T, Ob, Hip, BS, 
Str and 68% in cerebellum
no difference in DA, DOPAC, 
HVA, NE, NM in C, T, Ob, 
Hip, BS, Str and cerebellum
[175]
Tph2
-/- constitutive, 
complete
C57Bl/6, 
6th 
generation
less than 1-4% is left in the 
brain
complete absence of 
5-HT in the raphe 
nuclei
mSERT is 
present in the 
raphe
no detectable 
mTph2 
expression
no detectable reduction in 
the whole brain content of 
NA, glutamate, GABA, DA, 
DOPAC or HVA
[4]
Tph2
-/- constitutive, 
complete
near complete absence of 
serotonin in cerebral 
cortex, cerebellum, Hyp, 
BS
no detectable 
mTph2 
expression in 
the brainstem
around 15% increased levels 
of NE in the whole brain
[218]
Tph2
-/- constitutive, 
complete
complete absence of 
serotonin
complete absence of 
5-HT or TPH2; no 
TPH2 protein is 
detected by western 
blot
unchanged 
protein levels of 
SERT and Lmx1b 
[195]
Tph2
-/- constitutive, 
complete
reduction by about 15% [125]
Tph2
-/- constitutive, 
complete
C57Bl/6 
(97%)
1,1% in RR, 3,8% in Hip, 
6% in FC and
3,7% in T
 complete absence 
of TPH2 in the raphe 
nuclei
presence of 
SERT on the 
plasmatic soma 
membrane and 
projecting 5-HT 
fibers,in Hip; 
VMAT is present 
in raphe neurons; 
In the
presence of 10 
mM 
phenylephrine 5-
HT neurons show 
regular firing rate
reduction in NE by 28.3% in 
RR, 38.6% in Hip, 43.3% in 
FC and 29.5% in T; DA level 
reduced by 71,9% in Hip and 
by 67,7% (relative to Tph2
-/-
); 
reduction in NA neurons by 
33.8% in arterior LC, but no 
difference in posterior LC; no 
difference in DA cell clusters 
in SN, VTA and A8
[78]
Tph2
Nes-cre
constitutive, in 
all neurons = 
cells 
expressing 
nestin
C57/BL6
some remaining 
TPH2-positive cells 
mainly in the dorsal 
part of rostral raphe 
region
no difference in 
the expression of 
5-HT1a, 5-HT1b, 
5-HT2a, 5-HT2c 
receptors, 
serotonin 
transporter (Sert) 
in F and PFC, 
Str, Hip, Hyp, A, 
rostral and 
caudal raphe 
region, and 
entorhinal cortex
80%  and 90% 
mTph2 
reduction in 
rostral  and 
caudal raphe 
regions, 
respectively
[110]
Tph2
Pet1-cre
constitutive, in 
5-HT neurons 
= cells 
expressing 
Pet1
C57/BL6 x
129/SvEMS 
x
FVB/N
complete absence of 
5-HT in the raphe 
nuclei
90%  and 95% 
mTPH2 
reduction in 
caudal and 
rostral raphe 
regions, 
respectively
[110]
Tph2
Pet1-icre
inducible, in 5-
HT neurons = 
cells 
expressing 
Pet1
C57/BL6 x
129/SvEMS 
x
FVB/N
some remaining 
TPH2-positive cells 
mainly in the dorsal 
part of rostral raphe 
region depending on 
the amount of 
tamoxifen injection 
and on the age of 
the animals
80% mTph2 
reduction in 
rostral and 
caudal raphe 
region
[110]
Tph2 ::eGFP-/-
constitutive, 
complete
C57Bl/6, 
9th 
generation
less than 5% in hind- and 
forebrain
complete absence of 
TPH2 in the raphe 
nuclei
no detectable 
mTph2 
expression
normal innervation of primary 
somatosensory, S1, pariental 
cortex; reduced innervation in 
SChN (more than 50%); 
increased innervation in the NA 
and hippocampus (more than 
50%)
increased  mBDNF by 27% 
in Hip, but unchanged in 
cortex and PVN.
[138]
Table 1: Central 5-HT levels, serotonergic neurons formation and matura-
tion, and other neurotransmitter systems in Tph2-deficient mice
RR: rostral raphe; Hip: hippocampus; FC: frontal cortex; T: thala-
mus; C: cortex; Ob: olfactory bulb; BS: brain stem; Str: striatum;
Hyp: hypothalamus; A: amygdala; PVN: paraventricular nucleus;
SN: substantia nigra; DA: dopamine; NE: norepinephrine; DOPAC:
3,4 - dihydroxyphenylacetic acid; HVA: homovanillic acid; NA:
noradrenaline; NM: normetanephrine; BDNF: brain-derived neu-
rotrophic factor
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nor difference in the levels of other neurotransmitters in the brain
[4, 80, 78, 138, 176, 219].
1.3.2 Mouse models with altered formation of serotonergic neurons
Besides mice lacking the serotonin synthesising enzyme, TPH2, there
are other mouse models with reduced central serotonin levels due to
disrupted formation of 5-HT neurons.
Lmx1b-knockout mouse line Lmx1b-knockout mice die in utero
[55]. Lmx1b is responsible for the development of not only serotoner-
gic neurons but also of other neurons in the CNS, and other tissues
such as kidney and limb.
Lmx1bPet1−cre mouse line Disruption of Lmx1b gene in only
Pet-1 expressing cells (Lmx1bPet1−cre) allowed to specifically dis-
rupt the expression of Lmx1b in 5-HT neurons [227]. In the brains
of adult Lmx1bPet1−cre mice there are just residual amounts of sero-
tonin. Moreover, there is almost a complete loss of 5-HT neurons in
the raphe or their fibers at the target areas [227]. Interestingly, no
changes in the amount of DA or NE in the brain of Lmx1bPet1−cre
mice were reported.
Lmx1bPet1−icre mouse line Inducible deletion of Lmx1b in the
Pet1 expressing cells in the adulthood causes reduction of central 5-
HT by 40% and a decrease in the amount of TPH2-positive neurons
by 85% [188].
Pet1-knockout mouse line Disruption of another factor im-
portant for central serotonin neuron formation, Pet1, causes an 80%
reduction in the number of 5-HT neurons in the raphe and 85-90% de-
crease in central serotonin in the cortex, hippocampus, and caudate
without significant changes in DA levels [89].
Pet1Pet−icre mouse line Inducible disruption of Pet1 during
6-8 weeks of adult life (Pet1Pet−icre) results in reduction of Pet1
expression by 70% in rostral raphe nuclei [124]. This leads to 50%
reduction in Tph2 expression and a drop of central serotonin levels
to 25%. Surprisingly, Pet1 disruption induced in adulthood did not
cause any changes in serotonin content or formation of 5-HT neurons
in B1-B3 raphe nuclei. In contrast, after tamoxifen treatment Pet-1
mRNA was decreased by more than 70% in B5-B9 nuclei [124].
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1.3.3 Mouse models with impaired serotonin storage, release and reuptake
Mice with disrupted 5-HT storage, release, or reuptake represent ano-
ther type of hyposerotonergic models.
Vmat2-knockout mouse line Mouse lacking VMAT2 are not
able to store also other monoamines apart from serotonin, and there-
fore, die within a few days after birth [6, 66, 215].
Vmat2Sert−cre mouse line . To overcome the lack of specificity
Vmat2 was ablated in SERT-expressing cells (Vmat2Sert−cre) [146].
In this mouse model a dramatic decrease by 92-96% (depending on
the region) of serotonin was observed in the cortex, striatum, hip-
pocampus, and brainstem. DA levels in the striatum, and NA levels
in the hippocampus and cortex were unchanged. However, in the hip-
pocampus of Vmat2Sert−cre mice there was a 17% decrease in NA.
There was no detectable 5-HT immunoreactivity in the adult raphe,
while the amount of TPH2-positive cells was unchanged [146]. Fur-
thermore, mice lacking VMAT in serotonergic neurons show normal
fiber formation in cerebral cortex and hippocampus [146].
Vmat2Pet1−cre mouse line As both Sert and VMAT2 are tran-
siently expressed in a number of glutamatergic neurons and peri-
pheral organs during development [116], it is possible that some as-
pects of the phenotype observed in VMAT2Sert−cre mice could be
due to the deletion of VMAT2 in these cells during development. To
generate a more specific model mice with the raphe-specific inactiva-
tion of the VMAT2 gene were created by using the ePet1-cre mouse
line, where Cre is expressed exclusively in raphe neurons in the brain.
The brain serotonin level in VMAT2Pet1−cre mice was uniformly
decreased by 75% in the cortex, hippocampus, striatum, and brain-
stem in prenatal E18 embryos, postnatal pups as well as in adults. No
changes in DA levels were found.
Sert-overexpressing mouse line Another mouse model with
reduced central serotonin levels is a SERT-overexpressing mouse [100].
This mouse shows a 2-fold increase in the amount of SERT mRNA,
and 3-fold increase in the amount of SERT binding sites in the brain.
Furthermore, the level of central serotonin decreased from 15 to 30%
depending on the region. The extracellular 5-HT levels are reduced
by 50-60% [100].
Interestingly, brain serotonin levels in mice lacking SERT are drama-
tically decreased. Thus, one might consider it as one of the hyposero-
tonergic mouse model. However, microdialysis studies revealed ele-
vated extracellular 5-HT levels in the brain [135].
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5-ht1A receptor raphe-overexpressing mouse line 5-HT1A
receptor expression in raphe nuclei is more than 10 times elevated in
5-HT1A receptor raphe-overexpressing mice (5-HT1ARO) [11]. These
mice have a 25% decrease in 5-HIAA/5-HT ratio in the whole brain
lysate when compared to controls [11]. However, in the original and
follow up studies extracellular 5-HT levels in different brain regions
were not studied in these mice [11, 12, 34].
1.3.4 Mouse models with polymorphisms in Tph2 gene
It is known that certain mouse strains markedly differ in manifesta-
tion of different behavior traits. Zhang et al. first surmised that the dif-
ference in depression-like behavior between 129X1/SvJ and BALB/cJ
mice may be caused by altered TPH2 activity [224]. Indeed, sequen-
cing analysis revealed a (C1473G) single-nucleotide polymorphism in
the coding region of Tph2 between these two strains resulting in the
substitution of a highly conserved proline (Pro) residue with an argi-
nine (Arg) at position 447. Consequently, it led to lowered enzyme
activity in vitro [172, 224]. Moreover, 5-HT content in the brain was
reduced by approximately 50% in the mouse strains carrying only the
1473G allele in comparison to mice homozygous for the 1473C allele,
which was also confirmed in an F2 intercross [172, 224].
However attempts to create congenic lines that differ only in the
mTPH21473 polymorphic allele revealed controversial results. Osipova
et al. showed that transfer of the 1473G allele into the C57Bl/6J genome
over 3 generations (B6-1473G (G/G)) significantly decreased TPH2
activity in the brain [151]. Another study instead revealed that breed-
ing the 1473G allele from DBA/2 mice over eight generations to the
C57Bl/6 background did not result in difference in the 5-HT content
in brain regions [194]. Recently in a third study it was shown that
backcrossing 1473G polymorphism to C57BlB/6 background over 10
generations results in unchanged serotonin content either in the fore-
brain, midbrain, or in the whole brain [20]. Moreover, extracellular
levels of 5-HT in dorsal and medial raphe nuclei were not different
between C57Bl/6 mice carrying either 1473C or 1473G alleles [20].
At last, Beaulieu et al. generated knockin mice expressing a mutant
form of Tph2. This mutation was engineered equivalent to the human
R441H mutation found to be associated with major unipolar depres-
sion [17]. TPH2 activity in R439H TPH2 knockin mice was reduced
by 80% in the striatum, cortex and hippocampus, while the expres-
sion of SERT was unchanged [17]. Extracellular 5-HT levels in frontal
cortex and hippocampus were decreased by more than half in these
Tph2 knockin mice [99].
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A I M S O F T H E S T U D Y
Serotonin (5-hydroxytryptamine, 5-HT) was given a close attention
since its discovery due to its involvement in the pathology of diverse
psychiatric disorders and drug action. However, lack of suitable phar-
macological or genetic tools to specifically influence the central but
not the peripheral serotonin system did not allow drawing final conc-
lusions about the processes that are directly influenced by serotonin
in the brain.
In this study I took advantage of newly generated mouse models
with complete or partial reduction in activity of TPH2, the enzyme
responsible for central serotonin synthesis, to investigate the impact
of this neurotransmitter on development, brain neurochemistry, and
beha9vior.
Using these animal models I aimed at clarifying the following specific
questions:
1. What is the consequence of life-long brain serotonin depletion on
mouse prenatal and postnatal development?
In order to answer this question I assessed pathways involved in
growth retardation of Tph2-deficient pups. In particular, functiona-
lity of the hypothalamo-pituitary-adrenal axis, lipid metabolism, ther-
moregulation, and the behavioral response to isolation were studied
during the first postnatal weeks.
2. Does partial inactivation or complete depletion of TPH2 change
central 5-HT levels and behavior?
To determine the role of brain serotonin in behavior first mice lacking
Tph2 were tested for alterations in general activity, olfaction, memory
formation, adult neurogenesis, aggressive, anxiety-, and depression-
like behaviors. To compare complete absence with partial inactiva-
tion of TPH2 anxiety- and depression-like behavior in mice with dec-
reased TPH2 activity were evaluated. To test for potential compen-
satory mechanisms I checked 5-HT1A receptor function and serotonin
metabolism in the brains of hyposerotonergic animal models. In addi-
tion, the ability of selective serotonin transporter inhibitor, fluoxetine,
to exert its actions on anxiety- and depression-like behaviors as well
as brain neurochemistry in the partial or complete absence of sero-
tonin was assessed.
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M AT E R I A L S A N D M E T H O D S
3.1 materials
3.1.1 Reagents
Name Company, city
5-HIAA Sigma, Steinheim
5-HT Sigma, Steinheim
5-HTP Sigma, Steinheim
Acetic acid Roth, Karlsruhe
Agarose Lonza, Switzerland 
Ascorbic acid Sigma, Steinheim
Bromophenolblue Sigma, Steinheim
DAPI Sigma, Steinheim
DEPC Serva, Heidelberg
DNaseI Boehringer Mannheim, Mannheim
dNTPs Amersham Bioscience, NJ, USA
Donkey serum Sigma, Steinheim
DTT Sigma, Steinheim
EDTA Sigma, Steinheim
Ethanol Roth, Karlsruhe
Ethidiumbromid Sigma, Steinheim
First strand buffer Invitrogen, Darmstadt
Glucose Sigma, Steinheim
Glycerol Roth, Karlsruhe
HCl Roth, Karlsruhe
KCl Roth, Karlsruhe
MgCl2 Roth, Karlsruhe
M-MLV Invitrogen, Darmstadt
NaCl Roth, Karlsruhe
NaOH Roth, Karlsruhe
PCA Sigma, Steinheim
PFA Fischar, Germany
Proteinase K Invitrogen, Darmstadt
Random Hexamer Primer Boehringer, Mannheim
Rnase A Promega, Madison, WI
RNasin Promega, Madison, WI
SDS Serva, Heidelberg
Sucrose Roth, Karlsruhe
Taq polymerase Invitrogen, Darmstadt
TissueTek Sakura, Netherlands
Tris Roth, Karlsruhe
Triton X-100 Sigma, Steinheim
Trizol Invitrogen, Darmstadt
Tween 100 Sigma, Steinheim
Chemicals
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Chocolate cookie Bisquiva GmbH, Germany
Powder milk Marken-discount AG&Co.AG, Germany
Vanillin Sigma, Steinheim
High fat diet (45% fat) Ssniff, Soest
Normal chow (0.25%sodium) Ssniff, Soest
5-HTP Sigma, Aldrich
8-OH DPAT Tocris-bioscience, Wiesbaden-Nordenstadt
BrdU Sigma, Aldrich
fluoxetine Ratiopharm, Ulm
hIGF-1 Cellsciences, Canton MA
NSD-1015 Sigma, Aldrich
tryptophan Roth, Karlsruhe
WAY 100635 Tocris-bioscience, Wiesbaden-Nordenstadt
Reagents used for behavior tests
Diets
Reagents used for animal treatment
Table 2: Chemicals, reagents, enzymes and animal diets used in the study
3.1.2 Kits and Markers
Name Company, locaon
100 bp Marker Biolabs, USA
ABC Kit Vector laboratories, USA
Affymetrix 1. ST Affymetrix, USA
IGF-1 ELISA Diagnostic System Laboratories, USA
Leptin ELISA R&D System, UK
RNeasy Mini Kit Qiagen, Hilden
RT2 qPCR primer assay for Tph2 Sabioscience, USA
WT expression and labelling KIT Qiagen, Hilden
Φ174 DNA/BsuRI (HaeIII ) Marker, 9 Fermentas, Burlington, CDN 
Table 3: Kits and markers used in the study
3.1.3 Antibodies
Anbody Diluon Company, locaon
Primary
Growth hormone, rabbit   1:1000 Millipore, Germany
BrdU, rat  1:500 Biozol, Germany
Secondary
anti-rabbit AlexaFluor488  1:1000 Invitrogen, Germany
anti-rat biotin-SP  1:500 Jackson ImmunoResearch, USA
Table 4: Primary and secondary antibodies used in the study
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3.1.4 Equipment and expandable material
Name Company, locaon
8 channel pipette Biohit, Rosbach v.d Höhe
Accu Check Roche, Manheim
AlphaImager (UV) Alpha Innotech, Germany
Automatic Pipette Witoped XP Witeg Labortechnik GmbH, Wertheim 
Camera Panasonic, Japan
Centrifuge 5415C Eppendorf, Hamburg
Centrifuge Sorvall RC 5C Heraeus, Hanau
Cryostat Leica, Germany
Falcon tubes TPPR Trasadingen, Switzerland
FastPrep MP Biomedicals, France
Fine balance Kern&Sohn GmbH, Germany
Fluorescent microscope Keyence Corp., USA
Incubator Binder, USA
InfraMot TSE systems, Bad Homburg
Microwave 8020 Privileg, Fürth
Nanodrop Thermo Scientific, USA
PCR tubes Biozym Scientific GmbH, Oldendorf
pH Meter pH Level 1 WTW, Weilheim
Pipettes Gilson Disposable pipettes CellstarR 1, 2, 5, 10, 25ml
Power supply for the gel chamber Appligene, France
Real time PCR machine Biosystems, USA
SasLabPro Avisoft BioAcustics, Germany
Superfrost Plus slides Menzel Gläser, Braunschweig
Telemetry transmitters Data Science International (DSI), USA
Thermometer Thermo Fischer Scientific, USA
Thermomixer 5437 Eppendorf, Hamburg
USV microphone Avisoft BioAcustics, Germany
Viewer
2 
Biobserve, Bonn
Vortex: VibroFix Janke & Kunkel IKA, Germany
Water bath GFL, Burgwedel
Table 5: Equipment and expandable materials used in the study
3.1.5 Primers
Primers used for qPCR
gene of interest primer name primer sequence
SERT mSERT_fw_1 GGACAAAGAGGACTGCCAAG
mSERT_rev_1 GGCATAGCCAATGACAGACA 
TBP TBP_fw CCCTATCACTCCTGCCACACC
TBP_rev CGAAGTGCAATGGTCTTTAGGTC
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Primers used for animal genotyping
region of interest primer name primer sequence
annealing 
temperature
agarose 
gel, %
Tph2 deletion TPH34 5’AGC TGA GGC AGA CAG AAA GG 55
0
C 2
TPH54 5' CCA AAG AGC TAC TCG ACC TAC G
Neo3 5’ CTG CGC TGA CAG CCG GAA CAC
Tph2  1473G allele control for 5’ TTT GAC CCA AAG ACG ACC TGC TTG CA 65
0
C 2
control rev 5’ TGC ATG CTT ACT AGC CAA CCA TGA CAC A
G allele 5’ CAG AAT TTC AAT GCT CTG CGT GTG GG
Tph2  1473C allele control for 5’ TTT GAC CCA AAG ACG ACC TGC TTG CA 65
0
C 2
control rev 5’ TGC ATG CTT ACT AGC CAA CCA TGA CAC A
C allele 5’ CAG AAT TTC AAT GCT CTG CGT GTG GC
Table 6: Primers used in the study
3.2 methods
3.2.1 Molecular biology methods
dna isolation from tail/ear biopsies For genotyping of
experimental animals DNA was isolated from tail or ear biopsies. The
tissue was incubated overnight at 55◦C in 100 µl of the ear buffer
containing 1 mg/ml Proteinase K. Next the tissues were incubated
10 min at 95◦C in order to inactivate Proteinase K. Thereafter 750
µl of TE/RNase buffer were added to the sample in order to digest
RNA. After 15 min incubation at the room temperature (RT), 2 µl of
genomic DNA was used as a template for the PCR reaction.
dna isolation from hair follicles For some mice genoty-
ping needed to be performed more than once. To minimize the stress
of repeated ear or tail biopsies genotyping of animals was performed
from the hair follicles. A small bundle of fur together with the follicles
was collected. Hair roots were cut off and incubated 55◦C overnight
in 60 µl of hair buffer with 3 mg/ml proteinase K (prepared first as
stock 20 mg/ml in Tris-HCl, pH=7.5). Thereafter the same steps as
for DNA isolation from ear/tail biopsies were preformed.
Ear buffer
100 mM Tris pH 8.5
5 mM EDTA
200 mM NaCl
0.2% SDS
TE/RNase-buffer
20 µg/ml RNase A in 1x TE buffer
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TE buffer
10 mM Tris-HCl pH 8.0
1 mM EDTA
Hair buffer
10 mM Tris pH 8.3
50 mM KCL
0.5% Tween
rna isolation RNA from the whole brain was extracted with
Trizol reagent. 100 mg of the organs were diluted in 1000 ml of Trizol
and homogenized with Fast Prep. Further steps were performed ac-
cording to manufacture protocol. RNA from the hypothalamus was
isolated with the RNeasy Kit according to the manufacture protocol.
Independent from the method of isolation residual genomic DNA
was removed by DNase I treatment.
determination of nucleic acid concentration DNA and
RNA concentrations were determined by optical density (OD) 260
compared to OD280 in a spectrophotometer (Nanodrop). When OD
260/280 > 1.7, the protein concentration can be neglected and the con-
centration of nucleic acids was determined by the following ratio:
DNA OD260 = 1 = 50 µl/ml for double stranded DNA
RNA OD260 = 1 = 40 µl/ml
When OD260/OD280 < 1.7 the protein concentration of the solu-
tion is too high and requires additional purification steps (phenol-
chlorophorm extraction or purification on a column).
storage of nucleic acids For long-term storage DNA was di-
luted in DNase-free water or TE buffer and kept at -20◦C, RNA was
diluted in DEPC or RNase-free water from QIAGEN, and kept at -
80◦C. Primer stocks were diluted in DNase- and RNase-free water,
and kept at -20◦C. Before performing PCR the stock solutions were
diluted to working concentration in ddH2O and kept at -20◦C.
DEPC water
0.1% DEPC in ddH2O
overnight mixing at 37◦, than autoclaved
separation of nucleic acids on agarose gel DNA mole-
cules were separated by length using 1-3% (w/v) agarose gels, con-
taining 0.5 µg/ml ethidium bromide. DNA was mixed with 0.1V of
10 x Loading buffer, applied on agarose gel chambers and electropho-
rised at 1-8 V/cm in 1x TAE buffer. DNA was visualized under 300
nm UV light. The size and the approximate concentration of the DNA
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bands was determined by comparison with standardized molecular
weight markers (φX174 DNA/BsuRI (HaeIII) and 100bp ladder).
TAE buffer
40 mM Tris-Acetate pH 7.4
1 mM EDTA
10 x DNA Loading buffer
40% Sucrose
0.02% Bromphenolblue
in TE buffer
reverse transcription (rt) The synthesis of cDNA from to-
tal RNA was done using M-MLV first strand synthesis Kit. 1 µg of
total RNA was mixed with 1 µl of Random Hexamer primers, 1 µl 10
mM dNTPs and 0.5 µl RNasin in 12.5 µl volume. RNA was denatu-
rated for 10 min at 60◦C and quickly chilled to 4◦C. Then 7.5 µl of the
following mix was added:
5x first strand buffer 4 µl
0.1 M DTT 2 µl
RNasin (40 u/ml) 0.5 µl
M-MLV (200 u/µl) 1 µl
The reaction was incubated for 40 min at 37◦C. Than M-MLV was
inactivated at 80◦C for 10 min, afterwards the mix was kept on ice
until 2 µl were used for PCR reaction.
mouse genotyping For the genotyping the following PCR reac-
tion was set using TaqPolymerase:
genomic DNA 2µl
10x PCR buffer 5 µl
50 mM MgCl2 2.5 µl
10 mM dNTPs 1 µl
10 mM primer 1 1 µl
10 mM primer 2 1 µl
10 mM primer 3 1 µl
Taq polymerase (5u/ml) 0.5 µl
ddH20 36 µl
The reaction was kept on ice before transferred to preheated PCR ma-
chine. The program used for genotyping:
Denaturation 5 min 92◦C
Denaturation 45 sec 92◦C
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Annealing 30 sec at further specified ◦C for certain primer pairs
Elongation 30 sec 72◦C
Repeat 34x
Final elongation 10 min 72◦C
Forever 10◦C
Genotyping of animals was performed using primer combinations
specified in table Table 7. Information about the primer sequences, an-
nealing temperatures, and percentage of agarose gels used for DNA
separation are summarised in table Table 6.
PCR Bands/primers Band length, bp
Tph2 WT band 568
TPH54
TPH234
KO band 401
TPH54
Neo3
G/G control allele 523
Control for
Control rev
G allele 307
Control for
G allele
C/C control allele 523
Control for
Control rev
C allele 307
Control for
C allele
Tph2 PCR
WT band
KO band
+/+ +/- -/-
568 bp
401 bp
G or C allele PCR
523 bp
307 bp
control allele
G or C allele
Table 7: Primers used for genotyping of mice
quantitative real time pcr To quantify relative gene expres-
sion quantitative (real-time) polymerase chain reaction (qPCR) was
performed. Real-time PCR was run in a technical triplicate using
SYBR green reagent according to manufacturer protocol in a 384-
well plate format. For the qPCR reaction 9 µl of 2 ng/µl cDNA was
used. The expression of the Tph2 gene was quantified using RT2
qPCR primer assay, the expression of SERT — using primers listed in
the Table 6. Expression of gene of interest was normalized to TATA-
binding protein (TBP) mRNA expression. Oligonucleotides were cus-
tom made by Invitrogen. The method of Livak and Schmittgen [126]
was applied to compare gene expression levels between groups, using
the equation 2−∆∆CT .
microarray analysis For the analysis of gene expression pups
at the day of birth were sacrificed by cervical dislocation. Brains were
rapidly removed, hypothalamus was isolated, and then snap frozen.
Isolated and cleaned from genomic DNA RNAs were fragmented and
labeled ssDNAs with WT expression and Terminal labeling kits. The
labeled RNA was hybridized against the mouse gene 1.0 ST Array.
Differential expression of genes was calculated using Partek ANOVA
statistic followed by FDR multiple testing corrections. Resulting p-
values and FDR values indicated the probability of differential exp-
ression between the different conditions.
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3.2.2 Determination of plasma parameters
measurements of plasma hormone levels IGF-1 and lep-
tin levels were evaluated at postnatal day 35. Animals were anes-
thetized by an intraperitoneal (i.p.) injections of ketamine (100 mg/kg)
and xylazine (10 mg/kg). Blood was taken transcardially. 25 µL of
serum were used for IGF-1 measurement using a commercially avai-
lable EIA kit. 50 µl of serum was used for the leptin measurement
using a commercially available Leptin Kit.
glucose measurements Plasma glucose levels were measured
with the glucometer according to manufacturer protocol. To obtain a
drop of blood 1 mm of the mouse tail was cut with scissors.
3.2.3 Staining
growth hormone immunohistochemistry For the analysis
of pituitary glands in 2-day old Tph2-/- mice, the tissue was post-
fixated in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer for
4 hours followed by 2 hours 30% sucrose. After a short wash in PBS
heads were embedded in Tissue-Tek O.C.T compound and cryosec-
tioned in 14 µm coronal sections. Sections were dried for 2 hours at
room temperature and then stored at -80◦C. For immunohistochem-
istry, tissues were washed in PBS followed by PBST, and blocked
with 10% normal donkey serum. Slides were incubated overnight
at 4◦C with polyclonal rabbit anti-growth hormone. Anti-rabbit IgG
secondary antibody conjugated with Alexa-Fluor488 was applied the
next day. Fluorescence images were collected using a fluorescence mi-
croscope.
10 x PBS
for 1L ddH2O
80 g NaCl
2 g KCl
14.4 g Na2HPO2
2.4 g KH2PO2
pH to 7.4
PBST
o.1% Triton X-100 in 1xPBS
brdu labelling and quantification Mice were deeply anaes-
thetized with isoflurane and perfused transcardially with 0.9% sodium
chloride followed by 4% PFA in 0.1 M phosphate buffer. Brains were
removed from the skulls, postfixed in 4% PFA at 4◦C over night, and
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transferred into 30% sucrose. Sequential 40 µm coronal sections were
cut on a microtome and cryoprotected in cryo protection solution
(CPS). For BrdU staining, DNA was denatured in 2 N HCl for 20 min-
utes at 37◦C. Sections were then rinsed in 0.1 M borate buffer and
washed in Tris-buffered solution (TBS). Sections were stained free
floating with antibodies diluted in TBS containing 3% normal don-
key serum and 0.1% Triton X-100. Primary anti-BrdU antibodies were
applied in the concentration 1:500. Immunohistochemistry followed
the peroxidase method with biotinylated secondary antibodies, ABC
Elite reagent and diaminobenzidine (DAB) as chromogen. For BrdU
labeling, one-in-six series of sections of each brain were DAB stained,
and immunoreactive cells were counted throughout the rostra-caudal
extent of the dentate gyrus. Results were multiplied by six to obtain
the total number of BrdU-positive cells per dentate gyrus.
0.1 M phosphate buffer
for 1L ddH2O
13.73 g Na2HPO2
3.18 g NaH2PO2
0.1 M borate buffer
for 480 ml ddH2O
3.08 g Boric Acid
5 N NaOH
pH 8.5
10x Tris buffer solution (TBS)
for 1710 ml ddH2O
180 g NaCl
264.40 g Tris HCL
38.80 Tris base
Cryo protection solution (CPS)
250 ml 25% Ethylenglycol
500 ml 0.1 M PO4
oil red o staining Aliquots of fresh stool samples collected
prior staining were homogenised after adding water in a volume of
10 µl/mg stool. After centrifugation (200g, 5 min) 5 µl of supernatant
was applied to a glass slide, mixed with 5 µl of staining solution,
and examined by light microscopy [83]. For preparing the stock of
staining solution 0.3 g of Oil RedO was dissolved in 100 ml of isop-
ropanole. It was stirred overnight, filtered and stored at 4◦C. Prior to
staining two parts of distilled water was added to three parts of the
stock solution of Oil RedO [109].
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3.2.4 Animals
general animal handling All animal procedures were in ac-
cordance with the ethical principles and guidelines for care and use
of laboratory animals adopted by German local authorities correspon-
ding to the standards prescribed by the American Physiological So-
ciety. Mice were maintained in individually ventilated (IVC) cages,
34x19x13 cm at an ambient temperature of 22◦C, under a standard
light/dark cycle from 7 am to 7 pm, with free access to standard
chow and drinking water ad libitum.
animal breeding Tph2-deficient mice were on two genetic back-
grounds, C57Bl/6 and FVBN. To obtain Tph2 gene-deleted mice on
a pure genetic background, heterozygous Tph2-deficient animals on
C57Bl/6 background (6th generation) [4] were bred for further four
generations to C57Bl/6 mice (Charles River, Germany). Tph2-/- mice
on a FVB/N background were obtained by backcrossing heterozy-
gous Tph2-deficient animals with FVB/N mice (Charles River, Ger-
many) for 12 generations backcross (F12).
A B
Figure 3: Breeding scheme used for obtaining Tph2-/- , Tph2+/- , and
Tph2+/+ animals for A). pups USV, experiments at 30◦C, foot print
test, and activity measurement at postnatal day 35 and for B). all
the behavior, neurochemical and metabolic experiments
The pups USV, experiments at 30◦C, foot print test, and activity mea-
surement at postnatal day 35 were studied in mice on FVB/N back-
ground, derived from breeding Tph2+/- male mice with Tph2+/- fe-
male mice Figure 3(A). All the other experiments were performed in
mice on C57Bl/6 background, obtained by breeding Tph2+/- female
mice either with Tph2-/- or with Tph2+/+ male mice Figure 3(B). The
study of activity, muscle strength, anxiety- and depression-like behav-
ior, aggression, memory, and brain neurochemistry was performed
in 18-22 weeks old male mice. Neurogenesis was studied in female
26
3.2 methods
Tph2-/- and Tph2+/+ mice at the age of 32-37 weeks of age. The olfac-
tory habituation-dishabituation test was performed in 18-22 weeks
old male and female Tph2-/- and Tph2+/- (control) mice, and the hid-
den cookie test — in female Tph2-/- and Tph2+/- mice.
Figure 4: Breeding scheme used for obtaining experimental Tph2C/C ,
Tph2G/G , and Tph2G/- animals
To study the implication of partial reduction in central serotonin
on behavior and brain neurochemistry 4 groups of mice were used.
The first group was C57Bl/6 mice, homozygous for the 1473C allele
further referred to as Tph2C/C . The second group contained con-
genic C57Bl/6 animals homozygous for the 1473G allele (Tph2G/G
) generated by transferring the 1473G allele from DBA/2 mice via
breeding over seven generations to the C57Bl/6 background [194]
Figure 4. In the third group were mice heterozygous for the Tph2-null
allele on C57Bl/6 background (10th generation backcross)[4], further
called Tph2C/- . The last group of animals, Tph2G/- , was obtained
by breeding Tph2G/G (1473G on C57Bl/6 background) with Tph2-
deficient mice (Tph2-/- on C57Bl/6 background) Figure 4. Mice of the
above mentioned genotypes were used at the age of 20-26 weeks.
3.2.5 Behavior assessment
For all behavior experiments mice were habituated to the experimen-
tal room for at least one week, or if that was not necessary at least an
hour before testing. During this time repeated handling of animals
was done by the same experimenter who performed the tests. Mouse
behavior was video recorded for subsequent offline analyses by the
experimenter. For analysis of EPM data Biobserve software was used.
In all experiments the observer was blind to the genotype. The tes-
ting arenas if not specified were cleaned between trials or different
animals with water, and dried with the paper towels.
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activity measurements Locomotor activity was recorded in
the home cage by InfraMot system. The system is working through
sensing the body-heat image, infrared radiation. The sensor was pla-
ced on a top of a home cage over 5 days. The last 3 days of measure-
ments were analysed.
open field A large arena (50x50 cm) under low illumination (30
Lux) was used as an open field to measure locomotor activity. Each
mouse was placed into the arena facing the middle of the wall and
its activity was measured during 10 min. The total distance travelled,
time spent in the center and near the walls were calculated.
foot print test To evaluate the gate of mice the foot prints of
mouse hind paws were obtained by dipping them into the dye. The
mice were placed on a narrow (5 cm) gangway 45 cm long. The floor
of the gangway was covered with white paper. No pretraining was
used. Each individual mouse was given 3 trials. After all the trials
the mouse was placed for 1 min in an empty cage filled with about
1 cm of warm water in order to clean the paws from the ink. There-
after the mouse was transferred into its home cage. As a result, for
each mouse 10-15 clearly defined, single prints of foot steps were
obtained Figure 5. After drying the steps were analysed. The stride
length (distance between the hind paw of the same side) and stride
width (distance between hind paws of different side) were calculated.
a
b
Figure 5: Representative picture of foot prints. a – stride width, b – stride
length
recording and analysis of ultrasonic vocalization Ult-
rasonic vocalisation was measured in Tph2-/- and Tph2+/+ pups at
postnatal days 3 (Pnd3), 6 (Pnd6) and 9 (Pnd9). Pups were one by
one carefully isolated from their mother and nest, and transferred to
a new small glass chamber (10x8x7 cm; open surface) with the 2 cm of
sawdust. This chamber was in a sound-attenuated box made from Sty-
rofoam. Ultrasonic vocalizations were recorded during 10 min using
a condenser ultrasound microphone placed in the roof of the box, 10
cm above the floor Figure 6. The microphone was sensitive to frequen-
cies of 15-180 kHz with a flat frequency response (±6 dB) between
25-140 kHz. Prior to each test, the glass chamber was cleaned using
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microphone
roof of Styrofoam box
glass chamber
Figure 6: Representative picture of the testing chamber for recording pup
ultrasonic vocalisations.
70% ethanol solution, followed by water, and dried with paper to-
wels. The microphone was connected via an Avisoft UltraSoundGate
116Hbm device to a personal computer, where acoustic data were dis-
played in real time by an Avisoft Recorder and were recorded with a
sampling rate of 250,000 Hz in 16 bit format. For acoustical analysis,
recordings were transferred to SASLabPro, and a fast Fourier trans-
formation was conducted (512 FFT length, 100% frame, Hamming
window and 75% time window overlap). The spectrograms were pro-
duced at 488 Hz of frequency resolution and 0.512 ms of time reso-
lution. Call detection was provided by an automatic threshold-based
algorithm (amplitude threshold: -40 dB) and a hold-time mechanism
(hold time: 10 ms). Since no USVs were detected below 30 kHz, a
high-pass filter of 30 kHz was used to reduce background noise out-
side the relevant frequency band to 0 dB. The accuracy of call detec-
tion by the software was verified manually by an experienced user.
When necessary, missed calls were marked by hand to be included
in the automatic parameter analysis, and noise detected as a call was
excluded from the analysis. Total number of USV was calculated for
the entire session.
grip test According to the manufacturer’s instruction, mice were
hold by the tail and moved down until it grabbed the bar. Then the
mouse was moved against the direction of the force gauge until the
animal released the grid. The maximal grip strength value of animal
was noted. An average of four readings was obtained at each occa-
sion.
hidden cookie test This test is based on the assumption that
mouse driven by hunger will intensively look for hidden food in a se-
cure environment orienting itself mostly by olfaction. It can give fast
answer whether the mouse in general anosmic or not. Before testing
mice were trained for a week by receiving small chocolate cookie that
29
materials and methods
A C
open arm
cl
o
se
d
 a
rm
DB
Figure 7: Representative pictures of behavior tests for assesing: Anxiety-
like behavior: A) elevated plus maze and B). Marble burying
test; Depression-like behavior: C). Forced swim test; Olfaction:
D) habituation-dishabituation test.
was used afterwards for the test. 24 hr before testing the food was
removed, and the cages were changed in order to prevent the feeding
from food residues left in the bedding. The body weight and blood
glucose levels were controlled before and after food deprivation. On
the test day a mouse was placed in the arena (cage 42x25x18 cm, illu-
minated 10Lux) with the cookie hidden in a 5 cm of saw dust. Latency
to locate the buried food was considered as an index of olfactory abi-
lity. Directly afterwards the mouse was placed in a new cage with
the preweighed food. 30 min thereafter the amount of food eaten and
blood glucose levels were measured.
elevated plus maze This test is based on the inborn aversion of
rodents to open, bright illuminated spaces [157]. The maze consisted
of two open arms (30x5 cm, 300 lux illumination) and two closed arms
(30x5 cm, 10 lux illumination) that were enclosed by a sidewall on all
edges (height 15 cm) Figure 7(A). Mice were placed in the center of
the maze (central platform) facing the closed arm. Total arm entries,
percentage of entries into the open arm [(open arm entries/total arm
entries)*100] and time spent in open arms [(open arms/total session
duration)*100] were quantified. Arm entry was only defined when
the center of the body of the animal was on an arm by at least three
cm to distinguish true entries from stretched postures into the arms.
marble burying test Marble burying is a common test for val-
idating anxiolytic effect of drugs [148]. The test was conducted in a
new cage (equally in size to the home cage) containing evenly spaced
fifteen clear glass marbles (20 mm diameter) visible above of 5 cm of
sawdust Figure 7(B). During the test mice had access to food and wa-
ter, and the test cage was covered with a metal grid. After 30 min the
test was terminated by removing the mouse and counting the num-
ber of buried marbles. A marble was scored as buried if more than
two-thirds of it was covered with sawdust.
forced swim test This test, as originally described by Porsolt
[164], assesses the tendency to give up attempting to escape from an
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unpleasant environment, whereby fewer attempts are interpreted as
behavioral despair. Here we used a plastic beaker (17.5 cm diame-
ter, 24 cm high), filled with water (24◦-26◦C) to a height of 18 cm
Figure 7(C). The time mice spent floating on the water (immobility
time, sec) during 6 min as well as latency (sec) to the first immobility
episode were manually scored. A mouse was judged to be immobile
when it ceased struggling and remained floating motionless in water,
making only those movements necessary to keep its head above the
water. Swimming was defined as vigorous movements with forepaws
breaking the surface of the water.
habituation-dishabituation test This olfaction test allows
assessing the ability to distinguish smells between each other, and
the ability to get used to one smell. 30 min before testing the mouse
was put into fresh test cage (sized as home cage) with a closed plas-
tic lid. Each test cage was used only once. During next 10 min a dry
and clean cotton stick was introduced into the cage through the hole
for water bottle in order to decrease unspecific sniffing not connected
with the odor. Next four odors were tested along with water as con-
trol: vanilla, peppermint, female and male urine Figure 7(D). Each
smell was introduced three times for 2 min with a 1 min inter-trial in-
terval. In order to be able to test social odors (female and male odors)
only test mice that were familiar with the opposite gender were used.
Vanilla was dissolved in water. Peppermint was prepared freshly as
a water extract from peppermint leaves. Female and male urine was
collected at the day of testing from mice with which the tested mice
never had contact. The time mice spent sniffing different odors was
measured.
novelty suppressed feeding This test is based on a provoked
conflict between the fear of mice to enter bright illuminated spaces
and food seeking induced by hunger [21, 123]. Animals were food
deprived 23 hr prior testing. On the test day mice were first placed
into a new cage for 30 min. Then they were introduced into a new
brightly illuminated test environment (cage 42x25x18 cm, 350 lux il-
lumination in the center of the arena) where a single food pellet was
centrally placed. After the first feeding event animals were returned
to their home cages where they could eat pre-weighed food over a
period of 5 min. Latency to the first eating episode (time between
mouse introduction to arena with food pellet in the middle and the
first feeding event) was used as an index of induced anxiety-like be-
havior. The amount of food consumed in the home cage provided a
measure of appetitive drive.
resident intruder test The resident intruder test is based on
the territory defensive behavior against unfamiliar intruding cons-
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Figure 8: Schematic presentation of memory tests. A) and B) Morris water
maze: filled with water circular maze (1.2 m diameter) with 4 cues
of different shape and color on the side of it. During the three
testing days the platform stayed at one position, and during each
trial (from 1 to 6) of the same day mouse was placed in the same
position. C) Y-maze: each arm is randomly assigned the letter A,
B, or C.
pecifics [113]. Each single-housed resident male was confronted in
its home cage by a group-housed (five mice per cage) intruder male
FVB/N mouse for 10 min. Each intruder mouse was used only once
to avoid submissive/dominance effects after first interaction. Beha-
vioral interactions during each confrontation were recorded and sub-
sequently scored by an observer. Latency to the first attack, total
amount of attacks and cumulative duration of attacks were analyzed.
morris water maze One of the tasks to assess special memory
is the morris water maze (MWM) [209]. Mice were trained to find a
hidden platform in a circular maze (1.2 m diameter) using cues si-
tuated around the pool. The maze was placed alone in a room with
four cues on its walls Figure 8(A). Water was made opaque with milk
powder and kept at the temperatures 20-22◦C. Each mouse was given
6 trials a day during 3 consecutive days with an inter-trial interval of
1hr. The position of the transparent square platform (8cmx8cm) hid-
den 0.5cm under the water during the testing days was not changed
Figure 8(B). Each day the mouse was released from one of the sides
of the pool and was given 120 sec to find the platform. To introduce
mouse into the pool it was placed into an opaque plastic beaker with
the lid attached to a stick. It helped to prevent visual orientation du-
ring the release of the mouse. Next the cup was moved to the wall
of the pool and turned so that the mouse glided into the water fa-
cing the wall. Irrespective at the trial performance mice were guided
to the platform and allowed to remain there for at least 15 sec. The
mouse was removed from the platform with the help of a wire mesh
attached to a stick onto which it would readily climb. Between trials
mice were kept in single cages under infrared light and were allowed
to dry and warm up.
spontaneous alternations in y-maze Spontaneous alterna-
tions in the Y-maze are extensively used as a measure of working
memory [61]. The Y-maze was slightly illuminated (10Lux). Each arm
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of the symmetrical Y-maze was 30 cm long, 30 cm high, 3,5 cm broad
at the bottom and 15 cm at the top. Each arm was randomly assigned
the letter A, B, or C Figure 8(C). The mouse was placed in the middle
of the maze facing arm B and was given 10 min to freely explore the
maze. The amount and consequence of each arm entry was recorded
by the observer. Percent alternation was calculated as the number of
nonrepeating triads (for example, ABC, CBA, CAB, and etc.) divided
by the maximal possible alternations (total number of arm entries
minus 2) and multiplied by 100.
3.2.6 Telemetric measurement
PhysioTel PA-C20 pressure transmitters were implanted into the femo-
ral artery of 3 months old female mice and recordings of blood pres-
sure (BP), heart rate (HR) and locomotor activity were started 10 days
after the surgery. Data for the day/night-time activity and sleeping
time were averaged from 6 am to 6 pm and vice versa of 96 hours
recording time. The sleeping time was calculated from the locomotor
activity data. An animal was considered as sleeping when it was dis-
playing no activity during at least 5 minutes. More than 30 minutes
immobility was considered as an extended sleeping period. The lo-
comotor activity of animals was averaged for the non-sleeping time
periods during both day- and night-time.
3.2.7 Neurochemical assessment
To prepare brains for high-performance liquid chromatography (HPLC)
analysis, animals were anesthetized by intraperitoneal (i.p.) injection
of ketamine (100 mg/kg) and xylazine (10 mg/kg). Animals were
transcardially perfused with PBS containing 300 U/ml heparin to
remove the blood, containing peripheral serotonin. Brains were re-
moved, weighed, and snap frozen on dry ice. For the determination
of serotonin and its metabolites, frozen tissues were homogenised in
lysis buffer containing 10 µM ascorbic acid and 1.8% perchloric acid
(PCA), centrifuged for 30 min at 20 000 g, 4◦C, and the supernatant
was used for HPLC measurement. Tissue levels of 5-HTP, 5-HT, and
its metabolite 5-HIAA were analysed using high sensitive HPLC with
fluorometric detection [220]. Sample separation took place at 20◦C on
a C18 reversed-phase column using a 10 mM potassium phosphate
buffer, pH 5.0, containing 5% methanol with a flow rate of 2 ml/min.
Fluorescence of 5-HTP and 5-HT was excited at 295 nm and mea-
sured at 345 nm. For the evaluation of serotonin synthesis in vivo
animals were injected i.p. with 100 mg/kg of the AADC inhibitor
3-hydroxybenzylhydrazine dihydrochloride (NSD-1015) one hour be-
fore brain dissection. Tryptophan was injected i.p. in a dose of 100
mg/kg alone or in a combination with NSD-1015 one hour prior brain
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removal. Amounts of 5-HT, 5-HTP, and 5-HIAA were normalized to
the wet tissue weight for statistical analysis. Calculation of substance
levels was based on external standard values.
3.2.8 Animal treatment
fluoxetine treatment Behavior changes followed fluoxetine
treatment were assessed after oral treatment with the drug in a dose
of 20 mg/kg/day. Fluoxetine was prepared fresh every third day by
first dissolving it in a small amount of tap water, then filtering and
adding the required amount of drinking water. 2 weeks after treat-
ment mice were either sacrificed for further analysis of brain neuro-
chemistry, or respective behavior test was performed.
To investigate the role of fluoxetine on proliferation and survival of
precursor cells mice were divided to two groups. The first group was
injected i.p. once a day with fluoxetine in a dose 10 mg/kg (dissolved
in saline). The second group served as a control group, and received
the saline injection once a day. Both groups received the drug or saline
in a volume of 10 µl/g body weight during 21 day.
brdu treatment To analyse proliferation, animals received three
i. p. injections of bromodeoxyuridine (BrdU) in a dose of 50 mg/kg
(dissolved in saline) 6 hours apart at the day 22 after saline or fluoxe-
tine treatment, and were sacrificed 24 hours after the first injection.
Another group of mice was tested for survival of proliferating pre-
cursor cells 3 weeks after BrdU. In this case BrdU was injected three
times at day 0 (one day before fluoxetine treatment was initiated) in
a dose of 50 mg/kg (dissolved in saline) 6 hours apart, and animals
were sacrificed the next day after the last fluoxetine injection (day 22).
igf-1 treatment Recombinant human IGF-1 was dissolved in
saline first until the stock concentration 1 mg/ml. The aliquots were
stored at -20◦C. For the injections stock solution was dissolved with
the saline 10 times until the final concentration 100 µg/ml. hIGF-1
was injected from P5 till P19 twice a day in a dose 1 mg/kg/day,
subcutaneously, in an amount 10 µl/g BW. Body mass measurements
were performed on the selected days (D5, 8, 11, 14, 16, 18 and 20).
5-ht1A agonist-induced hypothermia Saline, 1 mg/kg 8-
OH DPAT or 0.1 mg/kg WAY100635 were injected i.p. in a volume
of 10 µl/g. Mice were injected first with saline, then one week later
with 8-OH DPAT, and another week later with a combination of WAY
100635 and 8-OH DPAT. Body temperature was measured using a
thermometer probe inserted about 10 mm into the rectum. The probe
was dipped in Vaseline before insertion and held in the rectum until a
stable temperature was obtained (about 6 s). Prior to substance injec-
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tions three baseline body temperature measurements were recorded
every fifteen minutes (time points -30 min, -15 min and 0). After the
initial baseline temperature reading at 0 min, mice were administered
sterile saline or 8-OH-DPAT, and body temperature was recorded ev-
ery 15 min during 90 minutes in total. A specific 5-HT1A antagonist,
WAY 100635, was injected at the time point -30 min, directly after the
first baseline temperature measurement, followed by 8-OH DPAT in-
jection at 0 min and temperature measurements every 15 min during
the following 90 min.
high fat diet To rescue growth retardation phenotype, the diet
containing 45% fat was given starting at P15 for 11 days. At P35 ani-
mals were sacrificed for further analysis.
30◦c experiment Pregnant female mice at the day 14 after plug
check were put in the chamber with the normal dark/light regime.
In this chamber the temperature was maintained at 30◦C. When the
pups were born the litter was kept there until the weaning. The body
weight was measured each second day.
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4.1 growth retardation in Tph2-deficient mice
4.1.1 Phenotype
Tph2-/- mice on FVB/N background were born in normal Mendelian
ratios and were undistinguishable from their Tph2+/- littermates at
birth. Analysis of late embryonic stages (E14 and E18) did not reveal
body or brain weight or size abnormalities Figure 9 (A,B). However,
starting 3-4 days after birth Tph2-/- pups were smaller in size, with de-
creased adipose tissue content and dry skin. The growth retardation
worsened up to 4-5 weeks of age Figure 9 (C). Interestingly, at postna-
tal day 7 (P7) Tph2-/- pups were almost twice lighter than the control
littermates, but there was no detectable difference in brain weight.
At P14 there was a small but significant difference in brain weights
between Tph2-deficient and control pups Figure 9 (D). No abnorma-
lities in feeding behavior in the pre-weaning period were detected —
pups were noticed to have suckling activity as well as a size of milk
pouches similar to control pups. Moreover, diminishing the competi-
tion for the milk by decreasing the litter size did not restore normal
growth. Although being smaller, at the age of 3-4 weeks Tph2-/- mice
showed hyperactivity and jumpiness. However, at P35 Tph2-/- pups
were as active as their control littermates in the open field Figure 10
(A).
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Figure 9: Growth retardation in Tph2-/- mice. A) Embryonic growth: no
significant reduction in body mass of Tph2-/- embryos compared
to control littermates was observed (E14 and E18 — embryonic day
14 and 18, respectively). B) Postnatal growth curves of control and
Tph2-/- pups show a delay in body mass acquisition. The growth
of the Tph2-/- mice becomes significantly different from that of
control mice by P6 (***p<0.001, two way ANOVA). C) Brain weight
gain over the first two postnatal weeks in Tph2-/- mice. Student’s
t-test, *P<0.05.
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Figure 10: Activity and gait in Tph2-/- mice at postnatal day 35. A) Tph2-/-
and control mice travel equal distance in the open field under
low illumination during 10 min. B) Stride length, measured in
cm as a distance between hindpaws of the same side. C) Stride
width, measured in cm as a distance between hindpaws of differ-
ent sides. D) Representative picture of steps obtained from cont-
rol and Tph2-/- mice.
Furthermore, at this age Tph2-deficient mice have unchanged gait
measured in the foot print test by the stride length and width Fig-
ure 10 (B,C,D).
4.1.2 In search for explanation: hypothalamic-pituitary-adrenal (HPA) axis
The HPA axis consists of hypothalamus, pituitary and adrenal glands,
which are in tight connection with each other through complex feed-
back mechanisms. It is known that the HPA axis is involved in the
regulation of metabolic processes (energy expenditure, feeding, and
growth). The hypothalamus produces a number of releasing hormones
to the pituitary gland that in turn stimulates growth. Hypothalamus
receives 5-HT innervation of various density, which mainly originate
from the B9 group of raphe nuclei.
gene expression in hypothalami of newborn Tph2-defi-
cient mice First the impact of central serotonin ablation on the
gene expression profile of the hypothalamus was assessed. Only mi-
nor alterations in hypothalamic gene expression were detected in
Tph2-/- mice at the day of birth in comparison to control pups. Ana-
lysis of differently expressed genes did not reveal any potential can-
didate gene which may be responsible for the observed growth retar-
dation phenotype Table 8.
growth hormone production by pituitary gland in Tph2-
deficient pups The next component of the HPA axis that trans-
lates signals from hypothalamus is the pituitary gland. One of the
important hormones of the pituitary gland is Growth Hormone (GH)
that stimulates growth and regeneration. Analysis of GH by IHC re-
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Gene Symbol RefSeq
fold change 
Tph2
-/-
 vs. WT p-value
Ifi27l2a NM_029803 -2,2 0,001
Atad4 NM_146026 -1,5 0,008
2410018E23Rik XM_912668 -1,8 0,015
AY026312 NM_133359 -1,6 0,015
Slamf7 NM_144539 -1,6 0,015
Olfr430 NM_146718 -2,3 0,019
Apon NM_133996 -1,8 0,020
Gzmc NM_010371 -1,8 0,035
Semg1 NM_017390 -1,7 0,044
Exoc3l2 ENSMUST00000011407 1,6 0,004
Clca2 NM_030601 1,5 0,009
Zfp353 NM_153096 1,6 0,009
6720416L17Rik ENSMUST00000100000 1,6 0,020
4932411G14Rik NM_177711 2,2 0,023
Ms4a6b NM_027209 1,5 0,029
Nkx2-6 NM_010920 1,6 0,030
1810037I17Rik NM_024461 1,5 0,038
Crygb NM_144761 1,5 0,043
Gtsf1l NM_026630 1,9 0,045
Krt8 NM_031170 1,5 0,046
down-regulated gnes
up-regulated gnes
Table 8: Growth retardation in Tph2-/- mice: gene expression analysis of
hypothalamus obtained from Tph2-/- and control pups at the day
of birth (D0). Genes which expression was more than 1.5 fold and
significantly (p<0.05) up- or down-regulated are shown.
vealed no differences in its production and distribution in Tph2-/-
pups at D2 in comparison to control littermates Figure 11(A).
plasma leptin and igf-1 levels in Tph2-deficient pups
Due to the short life-time and pulsatory excretion it is technically
impossible to measure the level of GH in plasma. However, IGF-1 is
excreted by the liver in response to GH stimulation, and its level can
serve as a marker of GH secretion. Plasma IGF-1 levels were markedly
decreased in growth-retarded Tph2-/- mice at p35 Table 9. Moreover,
plasma leptin level was dramatically decreased in Tph2-/- mice in
comparison to controls at this age Table 9.
BW, g IGF-1, ng/ml Lepn, pg /ml
Control (n=5) 20,6±0,4 838,6±4,2 2930±240
Tph2
-/-  
(n=3) 11,6±1,2* 212,4±4,5**    685±38**
FVB/N (n=6) 22,0±0,2 918,2±39,1 6463±839
FVB/N malnutrion (n=5) 18,6±0,4
###
349,3±20,5
###
2430±324
##
Table 9: Metabolic parameters in 35-days old Tph2-/- , control and mal-
nourished mice. Values are expressed as mean ± SEM. *p<0.05,
**p<0.01 Tph2-/- vs control. ##p<0.01, ###p<0.001 FVB/N malnutri-
tion vs FVB/N.
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Figure 11: Growth retardation in Tph2-/- mice. A) Representative im-
munofluorescence images of growth hormone (GH) in the pitui-
tary gland of 2-days old and control mice. B) Postnatal growth of
Tph2-/- pups under the treatment of IGF-1 is not accelerated in
comparison to untreated Tph2-/- pups (***p<0.001 vs. untreated
control mice, ###p<0.001 vs. hIGF-1 treated control mice). C) Post-
natal growth curves of pups brought up at 30◦C degree do not
differ from the litters grown up at room temperature (*p<0.05,
***p<0.001 vs. control mice raised at room temperature,#p<0.05,
###p<0.001 — at 30◦C degree, two-way ANOVA).
growth phenotype in igf-1 treated Tph2-deficient pups
Taking into account the low levels of IGF-1 I hypothesized that dys-
function of IGF-1 excretion, induced by altered GH release, is the
cause of delayed growth. To test this hypothesis pups were treated
from P5 to P12 with IGF-1. No improvement in body weight gain was
observed in treated Tph2-/- pups vs. untreated Figure 9(B). Similar to
untreated mice, a significant difference in body weight between IGF-
1 treated Tph2-/- pups and control mice was observed already at day
8 Figure 9(B). This difference persisted during the whole period of
treatment, arguing that the decrease in plasma IGF-1 level is rather a
secondary phenotype than the primary cause of growth retardation.
Indeed, wild type FVB/N mice brought up by mothers having re-
duced milk availability developed significantly reduced body weight
than the control pups of the same age, and showed decreased IGF-1
and leptin levels Table 9.
4.1.3 In search for explanation: metabolic abnormalities
growth phenotype of Tph2-deficient pups brought up at
30◦c Previously it was shown that adult Tph2-/- mice exhibit alte-
rations in body temperature control [4]. To test the hypothesis that
a thermoregulation deficit is the primary cause of growth abnorma-
lities during early postnatal life, pregnant mothers were placed at an
ambient temperature of 30◦C, and maintained at this condition for 2
weeks after the delivery. This had no effect on growth of Tph2-/- or
control pups Figure 11(C).
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fat digestion in Tph2-deficient pups During the postnatal
development in the pre-weaning period the main food source for
pups is mother’s milk. It contains mostly fat and few carbohydrates.
When pups grow up, they start eating the normal chow which con-
tains mostly carbohydrates. Thus, there is a switch in food composi-
tion between 2-3 weeks of age. Different metabolic processes are in-
volved in digesting and getting the energy from fat or carbohydrates.
Tph2-/- pups do not properly gain body weight in the pre-weaning
period, but after weaning they grow even faster than their control lit-
termates. Therefore, I hypothesized that Tph2-deficient pups despite
being able to suck the milk, are not able to properly digest it. In this
case keeping the mice on high fat diet (HFD) further after weaning
may delay the catch up in body weight.
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Figure 12: Growth retardation in Tph2-/- mice. A) Body weight of Tph2-/-
mice fed with HFD at P15-P35 is slightly improved in compari-
son to Tph2-/- pups under ND (*p<0.05, ***p<0.001 Tph2-/- on ND
vs. control mice on ND, ##p<0.001, ###p<0.001 Tph2-/- on HFD vs.
control mice on HFD, §§§p<0.001 Tph2-/- mice on ND vs. Tph2-/-
mice on HFD). B) Plasma leptin levels in Tph2-/- mice 2 weeks af-
ter HFD reached the level of control mice fed with ND. C) Plasma
IGF-1 levels of Tph2-/- mice 2 weeks after HFD reached the level
of control mice fed with ND (*p<0.05, **p<0.001, ***p<0.0001, two-
way ANOVA). HFD — high fat diet, ND — normal diet
However, giving HFD starting from 2 weeks of age even increased
the body weight gain of Tph2-/- pups Figure 12 (A). At P35 Tph2-/-
pups on HFD had higher body weight, increased levels of plasma lep-
tin and IGF-1 in comparison to Tph2-/- mice fed with ND Figure 12
(A,B,C). Moreover, after 10 days of HFD plasma leptin and IGF-1 le-
vels in Tph2-/- were normalised to the levels of control littermates on
a ND Figure 12 (B,C). However, Tph2-deficient pups fed with HFD
were still lighter than their control littermates fed with the ND Fig-
ure 12 (A).
In order to test the hypothesis of improper fat digestion during early
postnatal development in another experimental set up feces extracts
were stained with the Oil Red. The analysis showed no major differ-
ence in the amount of fat found in Tph2-/- and control pups’ feces
extracts Figure 13.
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control Tph2-/-
Figure 13: Representative Oil RedO staining of feces obtained from three
weeks old control and Tph2-/- mice.
4.1.4 In search for explanation: behavioral changes during early develop-
ment
ultrasonic vocalization of Tph2-deficient pups at the
pre-weaning period As mother’s care is very important for the
development during the pre-weaning period ability of Tph2-/- pups
to communicate their needs for care at the early postnatal days was
assessed. For this purpose ultrasonic vocalization of pups after their
separation from mother and nest was evaluated. At both P3 and P6
Tph2-/- mice emited twice less USVs in comparison to control pups
of the same age Figure 14. Furthermore, in contrast to Tph2-/- pups,
control mice exhibited a U-shaped profile of the amount of emitted
USV, with a clear peak at day 6 and reduction at day 9.
control
Tph2-/-
Figure 14: Amount of ultrasounds emitted by Tph2-/- mice at postnatal days
3, 6 is different from control pups, but undistinguishable at P9.
(*p<0.05 vs. Tph2+/+ , two-way ANOVA).
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4.2 behavioral and neurochemical abnormalities in Tph2-
deficient mice
4.2.1 Tph2 expression and serotonin levels
First the amount of Tph2 transcripts in the brains of Tph2+/- and
Tph2+/+ mice, containing one and two copies of the Tph2 gene, re-
spectively, was evaluated. Real-time PCR showed a 50% reduction in
Tph2 gene expression in the whole brain of Tph2+/- mice in compari-
son to Tph2+/+ mice Figure 15(A).
Next the amount of 5-HTP, serotonin and 5-HIAA in the whole brain
of Tph2-/- , Tph2+/- and Tph2+/+ mice was measured by HPLC. Tph2-/-
mice contained less than 2% of control 5-HT levels and no detectable
5-HIAA in the brain Figure 15(B), Table 10. However, only around 10
% reduction in brain serotonin levels was observed in Tph2+/- in com-
parison to Tph2+/+ mice, whereas the level of 5-HIAA was reduced
nearly by half Figure 15(B), Table 10.
Further the 5-HT synthesis rate in Tph2-/- , Tph2+/- and Tph2+/+ mice
was evaluated by blocking conversion of 5-HTP to 5-HT by NSD.
An around 20% decrease in accumulation of 5-HTP was observed in
Tph2+/- in comparison to Tph2+/+ mice Figure 15(C), Table 10. As ex-
pected Tph2-deficient mice accumulated less than 2% of 5-HTP com-
pared to Tph2+/+ Figure 15(C), Table 10.
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Figure 15: Tph2 expression and serotonin synthesis in Tph2-deficient mice.
A) Real-time PCR analysis of Tph2 expression in the brain (AU
- arbitrary units). B) 5-HT level in the whole brain (HPLC mea-
surement). Tph2+/+ 5-HT level is taken as 100%. C) 5-HTP level
in the whole brain 1 hr after NSD administration (100 mg/kg,
i.p.) (HPLC measurement). Tph2+/+ 5-HTP level is taken as 100%.
Data are shown as means ± SEM. **p < 0.01, ***p < 0.001 vs.
Tph2+/+ ; §§§p < 0.01 vs. Tph2+/- , one-way ANOVA with Bonfer-
roni correction.
4.2.2 Activity and muscle strength
Prior to behavior testing overall activity of freely moving Tph2-deficient
mice in their home cages during 24 hours within couple of days
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 5-HT  
(pg/mg) 
5-HIAA 
(pg/mg) 
5-HTP 
(pg/mg) 
5-HTP / NSD 
(pg/mg) 
Tph2
+/+
 753±16.3 366.3±34.9 3.7±0.3 329.1±14.0 
Tph2
+/-
 655.6±24.1
2
 217.0±11.7
1
 2.0±0.2
1
 266.7±7.1
1
 
Tph2
-/-
 13.6±1.0
1,3
 0.0±0.0
1,3
 0.0±0.0
1,3
 5.69±0.27
1,3
 
Table 10: Serotonin, 5-HIAA, and 5-HTP in the brains of Tph2-deficient
mice. Serotonin (5-HT), 5-hydroxytryptophan (5-HTP), and 5-
hydroxyindoleacetic acid (5-HIAA) levels were measured by
HPLC in whole brain lysates. Serotonin synthesis rate was eval-
uated by the accumulation of 5-HTP in the brain during 1 hour
after administration of the AADC inhibitor, NSD (5-HTP/NSD col-
umn). Values are normalised to mg of wet brain tissue. Data are
presented as means ± SEM. 1p < 0.001, 2p < 0.01 vs. Tph2+/+ ; 3p <
0.001 vs. Tph2+/- (one way ANOVA with Bonferroni’s correction).
was evaluated. First, activity was measured by telemetry that allows
recording the position of the animal every 5 sec Figure 16(A). Then,
the activity of mice was measured in the home cages with the In-
fraMot system Figure 16(B). Both experiments did not reveal any
differences in the activity of Tph2-/- mice in comparison to control
mice. However, analysis of sleeping episodes from the activity data
obtained in telemetric measurements revealed that Tph2-/- mice slept
more than control mice Figure 16(C,D).
Next, activity of Tph2-deficient mice in a unknown environment (open
field, under low illumination conditions) was evaluated. Tph2-/- mice
did not show any difference in locomotor activity in comparison to
Tph2+/- and Tph2+/+ mice Figure 19(A).
Furthermore, to assess another important parameter, muscle strength,
the grip test was performed. The maximum power that the mice disp-
layed during this test was not different between Tph2-/- , Tph2+/- , and
Tph2+/+ Figure 16(E).
4.2.3 Olfaction
Brain serotonin depletion has been shown to influence olfaction [161].
Therefore, olfaction in Tph2-/- mice was determined.
24 hr of food deprivation performed before the hidden cookie test
caused equal decrease in body weight by 15% in Tph2-/- and control
mice Figure 17(A). Moreover, fasted glucose levels were not different
between the 2 groups Figure 17(B). On the test day Tph2-deficient
mice needed the same 30 sec as controls to find and start eating a
hidden cookie in the middle of the tested area Figure 17(C). Further-
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Figure 16: Activity, sleep, and muscle power in Tph2-deficient mice. A)
Day-night activity of Tph2+/+ and Tph2-/- mice over four days
assessed by telemetric measurements. B) Locomotor activity of
Tph2+/+ , Tph2+/- , and Tph2-/- mice measured by InfraMot sys-
tem in the home cage over three consecutive days. C) Sleep: %
of time mice displayed no activity during 5 min period. Data are
averaged over for 5 consecutive days. D) Sleep periods over dark
and light phases. E) Grip test: muscle power, displayed as % of
controls. Data are shown as means ± SEM. ***p < 0.001, **p < 0.01
vs. control, one-way ANOVA with Bonferroni correction.
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Figure 17: Olfaction in Tph2-deficient mice.
Hidden cookie test A) Body weight and B) Glucose levels before
and 24 hrs after food removal. C) Latency to find the hidden
cookie. D) Amount of eaten food after finding the hidden cookie
during 30 min.
Habituation/dishabituation test: time male E) or female F) mice
spent sniffing water (control), vanilla, peppermint, and the urine
of female and male mouse.
*p < 0.05 vs. Tph2+/+ , #p<0.05, ##p<0.001, one-way ANOVA
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more, the amount of eaten food and glucose levels after the feeding
were the same in Tph2-/- and control mice Figure 17(B,D).
In another test for olfaction, the habituation-dishabituation test, Tph2-
deficient mice could distinguish when the same odor was introduced
a second or third time. Tph2-/- mice sniffed equal amounts of time
in comparison to control mice at the cotton stick dipped into all
odor solutions besides the peppermint Figure 17(E,F) when male
Tph2-/- mice sniffed this odor less during the first introduced time.
The longest sniffing time was observed for the urine of the opposite
gender. When this odor was introduced second and third time the
sniffing time decreased equally in Tph2-/- mice and control animals
Figure 17(E).
4.2.4 Aggressive behavior
In the RI test, Tph2-/- mice attacked the intruder almost six times
faster than Tph2+/+ mice (p=0.0002) Figure 18(A). Furthermore, the
number of attacks and the cumulative attack duration in the Tph2-/-
versus Tph2+/+ group were elevated sevenfold (p=0.0014 and p=0.01,
respectively) Figure 18(B,C). A qualitative analysis of attacks revealed
a striking difference between Tph2-deficient and Tph2+/+ mice: within
5 min of the test all mutant animals displayed aggressive bouts, while
only 22% of Tph2+/+ mice showed such behavior.
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Figure 18: Aggressive behavior in Tph2-deficient mice. Resident-intruder
test: A) Attack latency: time between the introduction of intruder
and the first attack of the resident. B) Total amount of attacks by
the resident. C) Cumulative attack duration during 10 min tested
time. Data are shown as means ± SEM. **p<0.01, ***p<0.001
vs.Tph2+/+ , §p< 0.05, §§p<0.01 vs.Tph2+/- , one-way ANOVA
with Bonferroni correction.
Though Tph2+/- mice tended to show an intermediate state of aggres-
sive behavior between Tph2-/- and Tph2+/+ mice, neither the diffe-
rences in the first attack latency nor the number of attacks were sig-
nificantly different between Tph2+/- and Tph2+/+ mice Figure 18(A,B)
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4.2.5 Anxiety-like behavior
In EPM, Tph2-/- mice spent significantly more time in the open arms
than Tph2+/+ and Tph2+/- (p=0.0161 and p=0.0133, respectively) Fig-
ure 19(C). Tph2-deficient mice also exhibited twice the amount of
open arm entries (p=0.0026 vs. Tph2+/+ , p=0.0054 vs. Tph2+/- ) Fig-
ure 19(D). However, total arm entries and total distance travelled were
comparable between mice of all three genotypes Figure 19(B).
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Figure 19: Locomotor activity and anxiety-like behavior in Tph2-deficient
mice.
Open field: A) Total distance travelled.
Elevated plus maze: B) Activity: total number of entries to closed
and open arms. C) Percentage of entries to open arms: entries to
open arm/total arm entries. D) Total time spent in open arms.
Marble burying test: E) Percentage of buried marbles: buried/in-
troduced amount of marbles. F) Locomotor activity during MBT.
Novelty supressed feeding: G) Latency to feed. H) Consumed
amount of food during 5 min after reaching the food pellet.
Data are shown as means ± SEM. *p<0.05, **p<0.01 vs.Tph2+/+
, §p< 0.05, §§p< 0.01, §§§p<0.05 vs.Tph2+/- , one-way ANOVA
with Bonferroni correction.
Analysis of locomotion in the EPM over time showed that Tph2-/-
mice extensively explored the brightest illuminated part of the open
arms already during the first 5 min of testing, while Tph2+/+ animals
did not enter the distal parts of the open arms during the whole 10
min of the test. Tph2+/- mice did not show any significant difference
compared to Tph2+/+ mice neither in the total time spent in open
arms nor in the open arm entries Figure 19(C,D).
The amount of marbles buried by Tph2-/- mice in the MBT was sig-
nificantly lower than that of Tph2+/+ and Tph2+/- animals (p=0.0199
and p<0.0001, respectively) Figure 19(E). Interestingly, the general ac-
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tivity of Tph2-/- animals during this test was almost two fold higher
than that of Tph2+/+ (p=0.0046) Figure 19(F). There was no signifi-
cant difference in the percentage of marbles buried by Tph2+/- mice
compared to Tph2+/+ mice Figure 19(E). However, Tph2+/- showed
an intermediate activity, significantly different from both Tph2-/- and
Tph2+/+ mice (p=0.009 and p=0.023, respectively) Figure 19(F).
In the NSF task, Tph2-/- mice needed less time to reach and start eat-
ing the food pellet in the center of the area compared to Tph2+/+ and
Tph2+/- (p=0.002 and p=0.017, respectively) Figure 19(G). Food con-
sumption, evaluated during the five minutes following the test did
not differ between the genotypes Figure 19(H). Tph2+/- mice did not
show a significant difference in the latency to reach and start eating
the food in comparison to both, Tph2+/+ and Tph2-/- Figure 19(G,H).
4.2.6 Depresssion-like behavior
In the FST, Tph2+/- mice did not show any significant difference in
comparison to Tph2+/+ in the total immobility time or the latency
to the first immobility episode, whereas Tph2-/- mice demonstrated
reduced struggling behavior Figure 20. They spent less time swim-
ming until the first immobility episode (p=0.0001) Figure 20(A) and
stayed longer immobile compared with Tph2+/- and Tph2+/+ litterma-
tes (p=0.005, in comparison to both genotypes) Figure 20(B) . More-
over, Tph2-/- mice showed an increase in immobility time during each
single 2 min episode compared with Tph2+/+ mice Figure 20(B).
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Figure 20: Depression-like behavior in Tph2-deficient mice. Forced swim
test: A) Latency to the first immobility episode. B) Immobility
time during 2 min intervals and the whole 6 min of tested period.
Data are shown as means ± SEM. *p<0.05, ***p<0.001, **p<0.01
vs.Tph2+/+ , §p< 0.05, §§p<0.01, §§§p<0.001 vs.Tph2+/- , one-way
ANOVA with Bonferroni correction.
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4.2.7 Effect of fluoxetine in Tph2-deficient mice
One of the first antidepressant, fluoxetine (FLX), has a capacity to
influence anxiety- and depression-like behavior [136, 210]. Therefore,
next effects of FLX treatment in mice lacking central serotonin were
assessed. Baseline levels of Sert expression were not different between
control and Tph2-/- mice Figure 21. Interestingly, after two weeks of
oral treatment with FLX Sert expression was more than 3 times up-
regulated in controls. However, the amount of Sert mRNA did not
change in the brain of Tph2-/- mice after FLX challenge Figure 21.
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Figure 21: Sert expression in Tph2-deficient mice. Real-time PCR analysis
of Sert expression in the whole brain. AU - arbitrary units, FLX -
fluoxetine. *p < 0.05, **p < 0.01 two-way ANOVA with Bonferroni
correction.
Effect of chronic FLX treatment was assessed first in the EPM. The
low anxiety phenotype, observed in Tph2-/- mice Figure 19(C,D), was
reversed by FLX treatment. After two weeks of FLX treatment Tph2-/-
mice spent less time in the open arms than untreated Tph2-deficient
mice Figure 22(A). Moreover, after FLX treatment Tph2-/- mice re-
mained in the open arms as long as untreated control mice. FLX
treatment did not have any effect on anxiety level in control mice
as Tph2+/+ mice spent the same amount of time in the open arms Fig-
ure 22(A).
Effect of chronic FLX treatment on depression-like behavior was as-
sessed in the FST. As it was reported above, Tph2-/- mice have reduced
latency to the first immobility episode, and increased immobility time
Figure 20(A,B), Figure 22(B, C). Two weeks of FLX treatment in 2 dif-
ferent groups of male mice resulted in 35% decrease in the amount
of time being immobile in Tph2-/- mice compared to untreated mice
of the same genotype (p<0.01) Figure 22(C). In contrast, FLX treat-
ment did not have any effect on the latency to the first immobility
episode in Tph2-deficient mice Figure 22(B). In fact, FLX treatment
did not have any influence on the immobility time in control mice
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Figure 22: Anxiety- and depression-like behavior of Tph2-deficient mice af-
ter two weeks of oral fluoxetine treatment.
Elevated plus maze: A) Time spent in the open arms.
Forced swim test B) Latency to the first immobility episode. C)
Immobility time during 2 min intervals and the whole 6 min of
tested period.
*p<0.05, **p<0.05 vs. untreated mice of marked genotype,
§§§p<0.001 vs. untreated control mice, one-way ANOVA with
Bonferroni correction.
Figure 22(C), even though the first immobility episode tended to oc-
cur earlier than in untreated mice (p>0.05) Figure 22(B).
4.2.8 Learning and memory
y-maze The percentage of spontaneous alternations was evaluated
in a Y-maze, a test which is known to be sensitive to impairments
in working memory. Both Tph2-/- and control mice completed the
task with the same degree of alternation which reached almost 70%
Figure 23(A). Tph2-deficient and control mice exhibit as well the same
amount of total arm entries confirming similar activity in the arena.
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Figure 23: Memory in Tph2-deficient mice.
Y-maze: A) % alternations: number of nonrepeating triads di-
vided by maximal possible alternations
Morris water maze: Percentage of failures to find the platform
B) over trials 1-6 at day 1 of testing or C) at the days 1-6 calcu-
lated as average of failures made over trials 1-6. Latency to find
the platform D) at day 1 of testing and E) at days 1 to 3 calcu-
lated as average distance needed to find the platform. F) Distance
travelled at days 1-3 calculated as average from 6 trials. The ave-
raged distance over trial 1-6 at day 1 control mice needed to reach
the platform is taken as 100%.
#p< 0.05, ###p<0.001 vs. mice of the same genotype of a marked
condition, two-way ANOVA with Bonferroni correction.
morris water maze Both Tph2-/- and control mice learned the
navigation task very rapidly. On the first testing day the amount of
failures to find the platform declined from trial 1 (40% for Tph2-/- and
50% for control mice) to trial 6 (all mice successfully reached the plat-
form) Figure 23(B,C). Already on the first day of testing the amount
of time needed to find the hidden platform decreased from trial 1
to trial 6 Figure 23(D). Cumulative statistics over 6 trials for each day
showed no difference between the latency to find the hidden platform
in Tph2-/- and control mice Figure 23(E). The distance travelled to the
platform as well decreased from Day 1 to Day 3 for both Tph2-/- and
control mice Figure 23(F) indicating that the path became more direct
from the place where the mouse was placed to the platform.
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4.2.9 Neurogenesis
Adult neurogenesis and memory formation are closely connected
[104]. Thus, next neurogenesis in adult mice lacking central sero-
tonin was assessed. First the amount of proliferating cells in adult
Tph2-/- mice was quantified. The number of proliferating cells in Tph2-
deficient mice 24 hours after the first bromodeoxyuridine (BrdU) in-
jection did not differ compared to controls Figure 24(A,B).
Next the survival of neural precursor cells in the adult hippocampus
following three weeks after BrdU injections was assessed. The num-
ber of surviving precursor cells were not different between Tph2-/-
and control mice Figure 24(C,D).
Then the amount of proliferating and surviving cells in adult Tph2-/-
mice after three weeks of FLX treatment was quantified. There was no
difference in the amount of proliferating as well as surviving cells in
Tph2-/- mice treated with saline or FLX Figure 24(B,D). Furtermore,
the number of proliferating and surviving precursor cells were not
different between Tph2-/- and control mice Figure 24(C,D).
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Figure 24: Neural proliferation in the adult hippocampus of Tph2-deficient
mice at baseline and under fluoxetine treatment.
Cell proliferation: A) Representative images showing no effect
of central serotonin deficiency as well as fluoxetine treatment
on proliferating cells. B) Quantification of the number of BrdU-
positive cells in the subgranular zone (SGZ) 24 h after the first
of three i. p. injections of BrdU, after 3 weeks of either saline or
fluoxetine (10 mg/kg/day) i.p. injection.
Cells survival: C) Representative images showing no difference
in the neuronal cell survival in Tph2-/- mice at baseline and un-
der fluoxetine (FLX) treatment in comparison to control mice.
D) Quantification of surviving BrdU-positive cells in SGZ after
3 weeks of i. p. injections of BrdU and three weeks of either of
saline or fluoxetine treatment (10 mg/kg/day).
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4.3 emotional and neurochemical abnormalities in mice
carrying Tph2 hypomorphic and null alleles
4.3.1 Anxiety- and depression-like behavior
First the effect of gradual reduction in Tph2 activity on emotional be-
havior was investigated. To this end, I tested C57Bl/6 mice (Tph2C/C
), congenic C57Bl/6 mice homozygous for the hypomorphic Tph2
1473G allele (Tph2G/G ), heterozygous Tph2-deficient mice (Tph2C/-
), and mice carrying one Tph2 1473G and one null-allele (Tph2G/- ) in
three paradigms for anxiety-like behavior and in two models of dep-
ression.
In the EPM, Tph2C/C , Tph2G/G , Tph2C/- , and Tph2G/- mice spent
equal time in the open arms of the maze Figure 25 (A, B). Moreover,
on the maze animals of all genotypes showed the same activity mea-
sured as total arm entries Figure 25 (C).
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Figure 25: Anxiety- and depression-like behavior.
Elevated plus maze: A) Total time spent in open arms. B) Per-
centage of entries to open arms: entries to open arm/total arm
entries. C) Activity: total number of entries to closed and open
arms.
Marble burying test: D) Percentage of buried marbles.
Novelty supressed feeding: E) Latency to the first eating episode.
Forced swim test: F) Latency to the first immobility episode. G)
Immobility time during 2 min intervals and 6 min of tested pe-
riod .
In the MBT, the amount of buried marbles was equal for all tested
groups Figure 25 (D).
In the third paradigm, NSF, Tph2G/G , Tph2C/- , and Tph2G/- mice
were as quick as Tph2C/C mice to reach and start eating the food pellet
in the middle of the tested arena Figure 25 (E). Food consumption,
evaluated during the five minutes following the test did also not differ
between the genotypes.
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In the FST, Tph2G/G , Tph2C/- , and Tph2G/- mice did not show any
significant difference in comparison to Tph2C/C animals in the latency
to the first immobility episode Figure 25 (F). Moreover, mice of all
genotypes stayed immobile for the same amount of time during each
two min intervals and during the total test duration (6 min) Figure 25
(G).
4.3.2 Serotonin content and metabolism
Next the impact of the Tph21473G polymorphism and the genetic
deletion of one Tph2 allele on serotonin levels in the brain was evalu-
ated. Tph2G/G and Tph2C/- mice showed a 9 and 13% reduction in cen-
tral 5-HT levels, respectively, relative to Tph2C/C mice, Figure 26(A),
Table 11. Surprisingly, carriers of just one copy of the hypomorphic
Tph21473G allele, Tph2G/- mice, showed only a 19% reduction in sero-
tonin content in comparison to Tph2C/C mice Figure 26(A), Table 11.
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Figure 26: Brain serotonin content and synthesis rate (HPLC measurement).
5-HT levels (A), 5-HIAA levels (B), and 5-HT turnover (ratio bet-
ween 5-HIAA and 5-HT) (C) in the whole brain lysates. D) 5-HT
in vivo synthesis: 5-HTP levels in the whole brain 1 hr after NSD
administration (100 mg/kg, i.p.). *p<0.05, **p<0.01, ***p<0.001 vs.
Tph2C/C , one way ANOVA with Bonferroni’s correction
To understand the reasons for such a subtle reduction in brain 5-HT
content in these mice next the 5-HT synthesis rate was analysed by
blocking conversion of 5-HTP to 5-HT by NSD. The accumulation
of 5-HTP was decreased by 33, 19, and 59% in Tph2G/G , Tph2C/-
, and Tph2G/- mice, respectively, in comparison to Tph2C/C animals
Figure 26(D), Table 11.
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Figure 27: Brain serotonin content and synthesis rate 1hr after tryptophan
treatment (100mg/kg, i.p., HPLC measurement). 5-HT levels (A),
5-HIAA levels (B), and 5-HT turnover (ratio between 5-HIAA and
5-HT) (C) in whole brain lysates. D) 5-HT in vivo synthesis : 5-
HTP levels in the whole brain 1 hr after NSD administration (100
mg/kg, i.p.). *p<0.05, **p<0.01, ***p<0.001 vs. Tph2C/C (one way
ANOVA with Bonferroni’s correction). Horizontal lines reflect the
levels measured in untreated Tph2C/C mice.
Despite considerable differences in the serotonin synthesis rate ob-
served between the strains, they still did not reach the values pre-
dicted from the in vitro activity of Tph21473G (50% of Tph21473C)
[151, 224] and inactivation of one Tph2 allele, which results in a 50%
reduction in Tph2 transcript levels Figure 15(A).
 5-HT  
(% to Tph2C/C) 
5-HT/ FLX 
(% to untreated Tph2C/C) 
5-HIAA 
(% to Tph2C/C) 
5-HIAA/5-HT 
(% to Tph2C/C) 
5-HTP/ NSD 
(% to Tph2C/C) 
Tph2
C/C
 100.0±2.6 74±2.9
### 100.0±9.5 100.0±8.76 100.0±4.3 
Tph2
G/G
 90.9±1.5* 78.7±0.7
## 76.2±1.4** 84.1±2.1* 66.7±2.3*** 
Tph2
C/-
 87.0±3.2** 67.3±1.9
### 59.2±3.2*** 68.1±4.8** 80.7±2.2*** 
Tph2
G/-
 80.52±1.6*** 42.7±1.8
###, *** 44.4±2.1*** 55.3±2.8*** 40.5±1.9*** 
 
Table 11: Serotonin content and synthesis rate at baseline and after 2
weeks of oral fluoxetine treatment (20 mg/kg/d, HPLC measure-
ment). Metabolite levels are presented as % of Tph2C/C levels. 5-
HT levels after FLX treatment are presented as % to untreated
(water dirnking) Tph2C/C mice. NSD was given i.p. in a dose
of 100 mg/kg 1hr before brain removal. Data are presented as
means± SEM. *p<0.05, **p<0.01, ***p<0.001 vs. Tph2C/C , ##p<0.01,
###p<0.001 vs. untreated mice of the same genotype (one way
ANOVA with Bonferroni’s correction). FLX – fluoxetine, NSD –
3-hydroxybenzylhydrazine dihydrochloride.
I hypothesized that this discrepancy may originate from a lack of the
substrate tryptophan (Trp) [63] and therefore evaluated the impact of
acute Trp administration on serotonin level and synthesis rate. After
acute Trp treatment, the amount of accumulated 5-HTP reached 50%
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in Tph2G/G and Tph2C/- animals and only 25% in Tph2G/- mice in
comparison to Trp-treated Tph2C/C mice Figure 27(D), reflecting the
5-HT synthesis pattern expected from Tph2 activity and expression.
However, the serotonin level after Trp injection was elevated to simi-
lar values in Tph2C/C , Tph2G/G , and Tph2C/- mice Figure 27(A). In
contrast, Tph2G/- mice failed to increase their brain serotonin values
following Trp administration, which remained below the level of unt-
reated control mice Figure 27(A).
The reason for the almost indistinguishable serotonin levels in Tph2C/C
, Tph2G/G , and Tph2C/- animals at both baseline and after Trp admi-
nistration became evident after the evaluation of the serotonin degra-
dation product, 5-HIAA. 5-HIAA was significantly decreased by 18,
47, and 67% in Tph2G/G , Tph2C/- , and Tph2G/- mice, respectively, in
comparison to Tph2C/C animals at baseline Figure 26(B), Table 11 and
by 24, 41 and 56%, respectively, in comparison to Tph2C/C mice after
Trp administration Figure 27(B). As a result at both conditions — ba-
seline and after Trp administration — there was a marked reduction
in serotonin turnover (5-HIAA/5-HT) in all mutant mouse lines in
comparison to the wild type Tph2C/C mice Figure 26(C), Figure 27(C),
Table 11.
In the last series of experiments we evaluated the possible effects of
chronic fluoxetine (FLX) treatment on serotonin metabolism in the
brain of mice with reduced serotonin synthesis. Two weeks after oral
FLX treatment the levels of central serotonin were reduced by around
20% in Tph2C/C , Tph2C/- , and Tph2G/G and by half in Tph2G/- mice in
comparison to control groups with water drinking mice of the same
genotypes Table 11.
4.3.3 5-HT1A receptor function
To evaluate the function of 5-HT1A autoreceptors in conditions of
gradually reduced Tph2 activity, we tested the body temperature re-
sponse to the single injection of 5-HT1A receptor agonist, 8-OH DPAT.
There was no difference between Tph2C/C , Tph2C/- , Tph2G/G and
Tph2G/- mice at baseline temperature measured 30 and 15 min before
treatment Figure 28(A) or in response to saline injection. However, 15
minutes after the injection of 8-OH DPAT there was a drastic drop of
body temperature in Tph2G/G and Tph2G/- mice by 3.5◦C and 4.5◦C,
respectively Figure 28(B), whereas only a slight decrease in body tem-
perature was observed in Tph2C/C and Tph2C/- mice Figure 28(B).
Furthermore, the hypothermic response was completely abolished
in Tph2-/- mice Figure 28(B). The difference in body temperature in
Tph2G/G mice persisted for one hour after 8-OH DPAT administration.
Furthermore, the body temperature of Tph2G/- mice did not norma-
lize even after 90 minutes had elapsed, whereas all other genotypes
had returned to baseline level by this time point Figure 28(A). The
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Figure 28: 5-HT1A receptor agonist-induced hypothermia. A) Temperature
response to the 5-HT1A receptor agonist, 8-OH DPAT. B) Tem-
perature drop 15 min after 8-OH-DPAT injection: delta body tem-
perature between time point 0 and 15 min. C) Temperature res-
ponse to the 5-HT1A receptor agonist after injection of the selec-
tive blocker of the 5-HT1A receptor, WAY 100635 (0.1 mg/kg i.p.
at the time point -30 min). *p < 0.05, **p < 0.01, ***p < 0.001, vs.
Tph2C/C under the same treatment. (ANOVA for repeated mea-
surements with Bonferroni’s correction).
hypothermic response was completely abolished by administration
of WAY 100635, a selective 5-HT1A receptor antagonist, 30 min prior
to 8-OH DPAT injection in all mouse strains Figure 28(C).
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5.1 role of central serotonin in postnatal development
In the first part of my thesis postnatal growth but not embryonic de-
velopment was shown to be dependent on brain serotonin.
Tph2-/- mice are depleted in brain serotonin by more than 95% [4],
and exhibit growth retardation during the first weeks of postnatal life
[4], Figure 9. Interestingly, another mouse model with impaired sero-
tonin storage, thus as well depleted in brain serotonin, Vmat2Sert−cre,
exhibit almost identical growth alterations. These mice are characte-
rized by normal weight at birth and most pronounced growth stun-
ting during the first 3 postnatal weeks corresponding to the pre-wea-
ning period. Furthermore, in the Vmat2Sert−cre mice, as in the Tph2-/-
mouse pups, a normalization of weight gain occurred after wean-
ing. Similarly, a growth retardation phenotype was observed in Pet1-
knockout and Lmx1bPet1−cre mice [92]. Furthermore, VMAT2 abla-
tion in Pet1-expressing cells in mice leads to 75% decrease in central
serotonin [146], and results in a similar trend and temporal course of
growth alterations, albeit to a lower degree [145]. It is possible that
such moderate transient growth retardation may exist in other hy-
poserotonergic mice, such as the R439H Tph2 knockin mice with 80%
reduction in central 5-HT levels [17]. However, no data about growth
of these mice have been reported.
In spite of life-long serotonin depletion, there is no visible alterations
in body and brain embryonic development in Tph2-/- mice Figure 9.
Instead, growth abnormalities became visible only during postnatal
life. This is unlike observations in mice born from Tph1-deficient
mothers, which were reported to display altered embryonic growth
[42]. This suggests that the maternal source of 5-HT, rather than emb-
ryonic 5-HT, is a crucial determinant of embryonic growth. Alter-
natively, it is also possible that other embryonic sources of 5-HT in
the body or the placenta could compensate for the lack of 5-HT pro-
duction in the brain [205, 197]. Another explanation is that somatic
growth relies on different trophic factors during embryonic and post-
natal life, with embryonic growth being dependent on maternal and
placental factors [181].
The growth phenotype in Tph2-deficient mice as well as in other hy-
poserotonergic models mentioned above, resembles the one caused
by general malnutrition with dry skin, lack of adipose tissue, and
reduction in organ size. Experiments performed with the rat pups
that were underfed during the first two weeks of life show a similar
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phenotype as Tph2-/- mice accompanied with increased lethality rate,
growth retardation, and impaired temperature regulation in adult-
hood [143]. Moreover, in Tph2-/- pups this phenotype is accompa-
nied by diminished plasma IGF-1 and leptin levels Table 9. However,
despite their emaciated appearance Tph2-/- mouse pups had filled
milk pouches and appeared to suckle normally, suggesting that they
had no feeding abnormalities. A similar phenotype was observed in
Vmat2Sert−cre. This is unlike what has been previously observed in
the constitutive Vmat2-deficient mouse, who had clear feeding ab-
normalities with empty milk pouches and weak suckling activity du-
ring early postnatal life [7, 66]. Vmat2-deficient mice showed massive
depletion of catecholamines in addition to 5-HT depletion. The al-
tered feeding behavior and the related growth deficiency is hardly
corrected when normal 5-HT brain levels are reinstated [42], sugges-
ting a causal role of the dopamine deficit in the altered feeding pheno-
type. Finally, measurements to reduce competition among pups had
beneficial effects on survival, but no visible effects on growth, sug-
gesting that altered access to the nipples was not a primary cause of
growth alterations. This suggested that an intrinsic metabolic defect
may occur in the Tph2-/- mice. Indeed, telemetric measurement indi-
cated an impaired body temperature and altered respiratory control
in Tph2-deficient mice [4], which may be an indirect cause of growth
alteration. However, attempts to maintain the pups in normothermia
had no visible effects on the growth phenotype Figure 11.
A remaining possibility to explain why decreased 5-HT causes the
exclusive deficit in growth during the early postnatal period could
involve the control of the somatotropic axis and growth hormone
(GH) secretion. Although in the Tph2-/- mice GH synthesis in the
pituitary gland was not altered Figure 11, it is possible that its se-
cretion may be modified. Indeed, previous evidence indicated that
5-HT modulates GH release in two different ways. On the one hand
it can directly activate the anterior pituitary gland [153]. On the other
hand it can facilitate GH release indirectly via a hypothalamic control
of GHRH and somatostatin (SST) secretion that control GH release
[186]. GH serum levels are particularly elevated during the first post-
natal weeks. 5-HT control of GH secretion appeared to be particularly
marked during this period [192]. Thus, GH release is less dependent
on central 5-HT after weaning which could explain growth normaliza-
tion in Tph2-/- mice after weaning. SST, being activated by 5-HT also
represses GHRH, resulting in a net inhibition of GH release. This in-
hibitory 5-HT-SST circuit may get more important during postnatal
life and could explain the compensation after weaning, since then the
lack of 5-HT would derepress the secretion of GH. However, there
was no evidence for this hypothesis in hypothalamic gene expression
profile of Tph2-/- mice Table 8.
Another possible cause of growth retardation in the postnatal period
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is inability to digest mother’s milk enriched with fat. However, giving
chow enriched with fat starting at the second week after birth even
improved the growth of Tph2-deficient pups Figure 12. Apart from
the hypotheses of HPA-axis disruption or improper fat digestion as a
cause of postnatal growth retardation in Tph2-/- pups, the nature of
this phenotype could lie in some behavioral functions such as ultra-
sonic vocalisation of pups. Pups vocalisation attracts attention of the
mother, thus notifying the mother that a pup needs some care. Loss
of maternal care leads to starvation, decrease in core body tempera-
ture of pups, and thus may result in malnutrition and death [93, 111].
However, the reduced USV observed in Tph2-/- pups is not neces-
sarily the primary cause of growth retardation. Tph2-deficient pups
may vocalize less since they are already weaker at P3 Figure 14. A re-
cent report about impaired sexual behavior in Tph2-/- mice revealed
as well impaired vocalisation to a social stimulus in these mice in
adulthood [125]. However, in this paper there was no data about pup
vocalisation at the first days of their life. Impaired pups’ USV was re-
ported in two models targeting serotonin receptors — 5-HT1A [216]
and 5-HT1B [30] receptor knockout mice. However, these mice are not
reported to be growth retarded.
5.2 Tph2-deficiency and its psychological consequences
The implication of brain serotonin in animal behavior has been re-
cognized already in the last century. Most of the studies were con-
ducted using pharmacological or genetic inhibition of serotonin re-
uptake and 5-HT receptors. However, the role of serotonin per se in
these studies was not completely clarified, because no suitable animal
model was available yet.
In the second part of my thesis mice with reduced activity of serotonin-
synthesising enzyme in the brain on a pure genetic background were
used to evaluate the consequences of complete absence of this neurot-
ransmitter in the CNS on behavior and brain neurochemistry.
unchanged activity of Tph2-deficient mice in the home
cage and in the new enviroment As any of the behavior
tests used in this study could be influenced by changes in animal
activity, first Tph2-deficient mice were examined for any alterations
in locomotion. Neither activity in the open field (new environment),
nor home cage activity measured by telemetry recording or InfraMot
system were different between Tph2-/- mice and control animals Fig-
ure 16. These findings go in line with other studies in Tph2-/- mice
[176, 210] as well as in other hyposerotonergic mouse models such
as Lmx1bPet1−cre [227], Pet1-knockout [89], and Sert-overexpressing
mice [100]. In contrast, decreased locomotor activity was reported
in mice with impaired Vmat2 expression, Vmat2 heterozygous and
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Vmat2Sert−cre mice [69, 146]. However, observed changes in locomo-
tion in these mouse models could arise from changes in other neurot-
ransmitter systems.
no changes in odor discrimination in Tph2-deficient mi-
ce Impaired serotonin neurotransmission might impair olfactory
sensation [161], thereby affecting the performance in behavior tests.
Therefore, prior behavior testing, female and male mice were tested
for the ability to detect and distinguish different odours. No major
difference in the response to unsocial or social stimuli in two tests for
olfaction was detected Figure 17.
exaggerated aggression in Tph2-deficient mice Seroto-
nin has been postulated to play a role in aggression [131, 201]. Low
cerebrospinal 5-HIAA was correlated with elevated aggression in hu-
mans [37, 38, 190] and monkeys [221]. Furthermore, low-Trp diet
resulted in increased aggressive behavior in humans [222], whereas
tryptophan enriched diet initiated a reduction of physical aggression
in subjects that had a history of elevated aggression [144]. Several ge-
netic variations in serotonergic genes have been linked to impulsive
aggression in humans [86, 177]. Moreover, a positive correlation bet-
ween low serotonin release and increased aggression was confirmed
by microdialysis in freely moving animals during the RI test [204, 64].
Inhibition of serotonin synthesis in rats led to increased aggressive-
ness, while enhancement of serotonin transmission suppressed agg-
ressive behavior [130].
Using Tph2-/- mice I showed that central serotonin deficiency led to
highly increased aggressive behavior in mice Figure 18. Interestingly,
this phenotype was observed not only in males, but also in Tph2-/-
females [4]. Thus, this model provides strong evidence for increased
aggression as a consequence of complete serotonin deficiency in the
CNS being in line with 2 recently published hyposerotonergic animal
models, TPH2 R439H knockin mice [17], and Pet-1 deficient animals
[89, 177].
It was recently reported that the absence of brain serotonin leads to
increased male-male mounting behavior in a 30 minutes social in-
teractions task [125]. This phenotype was not prominent during 10
minutes of the resident-intruder test performed in this study. More-
over, in several cases I had to interrupt the test due to the extreme
aggressiveness of Tph2-deficient animals. It can not be excluded that
defensive behavior of serotonin-deficient animals was misinterpreted
in the study of Liu et al. [125].
depression-like phenotype in Tph2-deficient mice A role
of serotonin in the etiology of depressive disorders was suggested
more than 50 years ago [28]. Later on formulation of the monoami-
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nergic theory of depression led to the development of antidepressive
drugs which increase the monoaminergic activity [128]. Moreover,
severely depressed patients treated with Trp or 5-HTP show symp-
tomatic improvement [206, 165], whereas, giving tryptophan-free diet
to depressed individuals elicits a relapse in patients getting treatment
with antidepressants [139, 179]. Mice depleted in brain serotonin ex-
hibited a lack of motivation to struggle in the FST that can be inter-
preted as a depression-like phenotype, supporting the monoaminer-
gic theory of depression Figure 20.
There is some discrepancy regarding this phenotype between these
results and recent data showing a slight anti-depressive effect in Tph2-
deficient mice on the second day of FST [176]. These conflicting fin-
dings could be due to several reasons, such as different analysis me-
thods - automated [176] versus manual (this study) [14] - or the two
day FST protocol [176], which is commonly used for identifying a dep-
ressive state in rats versus the one day protocol usually performed
for mice [46, 56]. Moreover, the study of depression-like behavior
by Savelieva et al. [176] was performed on a mixed genetic back-
ground (C57Bl/6Jx129S5/S), that may have masked the behavioral
effect of Tph2 gene ablation. Interestingly, there are reports that show
an increased immobility time in the TST in another genetic model of
central serotonin depletion — heterozygous VMAT2-knockout mice
[69]. However, in these mice levels of other neurotransmitters are also
changed and, therefore, the altered behavior in TST could not be in-
terpreted as only due to the depletion of central serotonin. Surpri-
singly, when VMAT2 was ablated only in SERT-positive neurons, the
behavior in TST was reversed: Vmat2Sert−cre mice showed a clear
anti-depressive phenotype in the TST [146]. However, these animals
were also on a mixed genetic background that may have veiled the
effect of central serotonin ablation. In the first description of Tph2-
deficient mice [176] no differences in the TST was observed at the
first day of experiment. Although both tests, TST and FST, are widely
used for the screening of antidepressants, the validity of these tasks
to evaluate symptoms of intrinsic depressive behavior is not so clear
[45]. Moreover, the sensitivity of these two tests to pharmacological
drugs is not identical, indicating that different neurochemical path-
ways may mediate the performance in these tasks [13]. Additionally,
mice being in two different inescapable situations (wet conditions in
FST and dry in TST) could use different strategies to struggle.
Several previous studies failed to detect any drastic alteration in dep-
ression-like behavior in models of serotonin depletion after PCPA
treatment [72, 149, 166]. The clear depression-like phenotype observed
in the FST in Tph2-deficient mice can be a consequence of a life long
depletion in serotonergic transduction versus short term effects of
PCPA.
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decreased anxiety-like behavior in Tph2-deficient mice
The behavioral evaluation performed in this study showed that Tph2-
deficient mice have decreased level of aversive behavior in approach-
avoidance-conflict tests Figure 19. It correlates with the hypothesis
that enhanced serotonergic transmission in the brain facilitates an-
xiety, whereas a decrease in extracellular 5-HT leads to reduced an-
xious behavior. This hypothesis, formulated in early the 1970-ies [217]
was further refined employing animal models with 5-HT depletion
by serotonin synthesis inhibition or lesions of serotonergic neurons
[8, 27, 44, 187]. Furthermore, studies in Sert overexpressing and Sert-
deficient mice [9, 94, 100], 5-HT1A-deficient animals [76], as well as
in very recently published hyposerotonergic mouse models includ-
ing Lmx1b-, Pet1-, or Vmat2-deficient animals [48, 107, 146] correlate
with this hypothesis. Despite being in line with the low-anxiety phe-
notype, observed in the EPM and NSF tests, the results of the MBT
poorly correlate with literature data from other genetic models affec-
ting the serotonergic system [176, 177, 226]. The opposite effects ob-
served in this study may originate from the differences in the genetic
background (pure C57Bl/6 used in this study vs. mixed in other stud-
ies) — a factor which may strongly affect serotonin-related behavior,
as already shown in Sert-knockout mice [94]. On the other hand, the
experimental setup used in this study was not identical to the one of
other studies: the protocols differ in several aspects, such as amount
of marbles, cage parameters, and test conditions. Moreover, one can
not exclude, that increased locomotion, unexpectedly observed du-
ring MBT and not reported in other studies, had an impact on results
of this test in our experiments.
unaffected memory in Tph2-deficient mice Serotonin fi-
bers form a dense network in the hippocampus. Most of the sero-
tonergic fibers originate from median raphe, although both median
and dorsal raphe innervate the ventral part of the hippocampus [68,
77]. Furthermore, serotonin fibers form dense projections to the hip-
pocampus during gestation. There is as well a notable expression of 5-
HT1A, 5-HT2A, and 5-HT2C receptors in hippocampus [49, 108, 156].
Serotonin is considered to play an important role in memory forma-
tion [31, 174, 218]. However, evaluation of hippocampal function in
serotonergic lesion models revealed controversial results [1, 97, 163].
In order to clarify the role of central serotonin in memory forma-
tion spatial memory in the water maze task and the Y-maze test was
assessed in Tph2-/- mice. Central serotonin ablation did not lead to
dramatic changes in spatial navigation in these paradigms, suggest-
ing that 5-HT has no direct effect on memory formation, or its effects
are masked by the compensatory mechanisms under the condition of
life-long central serotonin depletion.
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unperturbed precursor cell proliferation and survival
at baseline and after fluoxetine treatment in Tph2-defi-
cient mice Neurogenesis, formation of new granule cells, and
memory formation are closely connected [104]. Newly developed cells
are formed from the precursor cells in the subgranular zone (SGZ)
[5, 32, 103]. Numerous works explored the connection between hip-
pocampal function and 5-HT1A receptor deficiency or overexpression.
Acute deletion of 5-HT through pharmacological treatment [15, 108]
or 5-HT synthesis inhibition or lesion approaches by injecting the
neurotoxin 5,7-DHT [26] revealed controversial results which may
arise due to further severe impairments caused by the drug treat-
ment. However, until now there was no report elucidating how spe-
cific ablation of central serotonin affects hippocampal neurogenesis.
It is suggested that the antidepressant effect of some antipsychotics is
accomplished through hippocampal neurogenesis [175]. Accordingly,
a positive effect of FLX treatment on newly generated cells was re-
ported [133, 132, 175]. FLX is one of the mostly used antidepressant,
and it inhibits primarily the serotonin transporter thus increasing the
amount of 5-HT in the synaptic cleft. Surprisingly, at baseline nei-
ther proliferation nor survival of precursor cells were affected by life
long absence of serotonin Figure 24. Furthermore, no effect of FLX
treatment on neuronal cell proliferation or on survival was observed
neither in control nor in Tph2-/- mice. It is known that neurogenesis is
decreased with age [18, 112, 180]. Taking into the account the age of
the animals used in the study, I can not exclude that the effect of FLX
or central serotonin ablation was very subtle and undetectable in the
small numbers of proliferating/surviving cells seen at this age. Fur-
ther experiments with younger mice need to be performed in order to
clarify the consequence of central serotonin loss at baseline and after
FLX treatment.
normalised anxiety- and depression-like behavior in Tph2-
deficient mice after fluoxetine treatment Antidepres-
sive drugs were discovered before their mechanism of action was
identified. However, even today we cannot explain why treatment
with SSRI takes 2-3 weeks before one can see any behavior changes
in patients. Moreover, there are some patients who do not react or
show the opposite to expected behavioral responses to these drug.
Tph2-/- mice represent an exclusive model to identify probable tar-
gets of SSRIs which are independent of serotonin reuptake. In this
study I showed that 2 weeks of oral FLX treatment reduces immobi-
lity time in the FST in Tph2-deficient mice indicating normalization
of depression-like behavior Figure 22. Furthermore, SSRI treatment in
Tph2-/- mice led to the stabilization of anxiety-like behavior in EPM
Figure 22. These data strongly argue for existance of FLX targets be-
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yond the serotonin system, and further experiments need to be done
in order to unravel these pathways. One of the possible targets could
be GSK3β. In R439H TPH2 knockin mice GSK3β was shown to be
responsible for the observed behavior phenotype and antidepressant
actions [17]. In other studies it was shown that FLX can bind directly
to various serotonergic receptors (5-HT1A or 5-HT2C) with higher or
lower affinity. Furthermore, at high concentrations it can block the
noradrenaline transporter. In case of complete central serotonin defi-
ciency these secondary targets could become more important for FLX
action.
adequate behavioral responses in mice with gradually
decreased tph2 activity is associated with reduced sero-
tonin turnover and 5-ht1a receptor sensitization Next
I aimed to clarify the consequences of gradual reduction of TPH2 ac-
tivity in mice. For this purpose, a new mouse model carrying one
hypomorphic Tph2 allele and one Tph2 null allele (Tph2G/- mice) was
generated. For comparison wild type C57Bl/6 mice (Tph2C/C ), and
two previously characterized strains with around 50% reduction in
TPH2 activity (congenic C57Bl/6 mice homozygous for the Tph2 1473G
allele (Tph2G/G ) [194] and Tph2C/- mice, carrying one 1473C allele
and one null allele [4, 140] were used.
First I addressed the question whether a gradual decrease in TPH2 ac-
tivity leads to alterations in manifestation of anxiety- and depression-
like behavior similiar to Tph2-/- mice.
Evaluation of mouse behavior in three tests for anxiety (EPM, MBT,
and NSF) and FST for depression-like behavior revealed no difference
in Tph2C/- and Tph2G/G mice in comparison to Tph2C/C animals Fig-
ure 25. Surprisingly, a further decrease in TPH2 activity (in Tph2G/-
mice) did not have any impact on mouse behavior in these paradigms,
either.
Interestingly, the measurement of brain serotonin levels revealed only
a subtle reduction by around 20% in Tph2G/- mice and almost unaf-
fected levels of central serotonin in Tph2C/- and Tph2G/G mice Ta-
ble 11. These findings suggest the existence of compensatory mecha-
nisms involved in the normalisation of brain serotonin levels and
the maintenance of intact behavior in conditions of life-long reduced
TPH2 activity. In the search for such mechanisms serotonin metabolism
in models with partially reduced TPH2 activity was assessed. Eva-
luation of in vivo serotonin production clearly indicated that in all
studied models the serotonin synthesis rate, despite being reduced,
did not correspond to the expected values predicted from the in vitro
measurements of TPH2 activity (Tph2G/G mice) [194, 224] or Tph2
mRNA expression levels (Tph2C/- mice) Figure 15.
Tryptophan (Trp) availability is a critical factor affecting serotonin
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synthesis rate, and under normal physiological conditions TPH2 is
only 50% saturated with its substrate [63]. Therefore, brain serotonin
levels are dependent on the plasma concentration of free Trp and on
the plasma levels of the other large neutral amino acids which com-
pete with Trp for the large amino acid transporter at the blood brain
barrier. Indeed, administration of Trp in mice with partial TPH2 in-
activation rendered the 5-HT synthesis rate strictly correlated to the
predicted TPH2 activity in these animals Figure 27.
Nevertheless, the serotonin levels in the brain did not reflect its in
vivo synthesis rate in the studied mouse models neither at baseline
nor after Trp administration Figure 27. The evaluation of serotonin
turnover revealed that 5-HT content is mostly regulated at its degra-
dation level, which was stepwise decreased in mice with a gradual
reduction in 5-HT synthesis rate. Recently, a similar observation was
made in Tph2G/G congenic mice by another group [183]. However,
analysis of mRNA expression and in vitro activity of the serotonin
degrading enzymes MAO-A and MAO-B failed to identify any sub-
stantial differences between the strains that could be responsible for
the lower 5-HT degradation rate [183]. My data support these find-
ings since treatment with 5-HTP or Trp drastically increased not only
serotonin levels in the brain, but also lead to a higher accumulation
of its degradation product, 5-HIAA, arguing that in vivo MAO pro-
cessivity mostly depends on substrate availability. The amount of
5-HT readily available for MAO-mediated degradation is, however,
dependent not only on the serotonin synthesis rate, but also on the
activity of the vesicular monoamine transporter, VMAT2. The balan-
ce between packaging of 5-HT into the synaptic vesicles, where it
is protected from MAO-mediated oxygenation, and degradation of
the monoamine, which remains in the cytosol, provides a fine tun-
ing of the serotonin concentration in the cell. The monoamine storage
in vesicles is regulated by a G-protein dependent feedback loop that
allows modulating VMAT-mediated uptake based on the degree of
vesicular filling [95]. This regulation of VMAT activity was shown to
be dependent on the G-protein alpha-subunits of Go2 and Gq in neu-
rons and platelets, respectively [96]. In this respect, it is conceivable
that the Go2 dependent regulation of VMAT2 activity plays a role in
the process of elimination of excessive serotonin, and, thus, in the sta-
bilization of intraneuronal serotonin concentration.
Another potential mechanism facilitating an adaptation of the sero-
tonergic system to reduced TPH2 activity in mice is the modulation of
the 5-HT1A autoreceptor function on serotonergic neurons. 5-HT1A
is a key component of a negative feedback loop implicated in the inhi-
bition of 5-HT release upon activation of these cells [54]. The desensi-
tization of 5-HT1A receptors is a well-known phenomenon in models
with permanently increased 5-HT transmission triggered by genetic
ablation of SERT [60, 120] or its pharmacological inhibition by SSRIs,
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such as FLX [115, 119]. Surprisingly, attempts to identify an increase
in 5-HT1A expression or receptor density in different hyposerotoner-
gic models revealed either little or no difference [78, 99, 110]. To
study autoreceptor function in mice with reduced TPH2 activity, I
evaluated the hypothermic response to the 5-HT1A receptor agonist
8-OH DPAT, which is known to be mediated by 5-HT1A auto- but not
heteroreceptors [168]. Analysis of 8-OH-DPAT induced hypothermia
clearly indicated a functional sensitization of 5-HT1A autoreceptor in
mice with life-long reduced TPH2 activity Figure 28. Whether this
sensitisation occurs at the level of receptor expression, trafficking, or
its downstream signalling needs to be clarified [54].
Several studies revealed a link between reduced 5-HT1A function and
increased anxiety-like behavior in mice [76, 87, 154], whereas activa-
tion of 5-HT1A autoreceptors via agonist infusion decreases anxiety-
like behavior as measured in different behavior paradigms [50, 170].
Whether autoreceptor hypersensitivity observed in this study plays
a role in the maintenance of normal behavior response in anxiety-
related tests per se, or is just a marker of a renewed steady-state of
the serotonergic system established in conditions of life-long reduced
serotonin synthesis has to be further elucidated.
Since 2004, when a functional C1473G polymorphism was discovered
in the mouse Tph2 gene, several studies aimed to elucidate its impli-
cation in behavior. Congenic mice carrying this SNP on a C57Bl/6
genetic background were independently generated by several groups
[20, 151, 194]. Evaluation of serotonin content and metabolism re-
vealed a similar profile in all these mice, showing around 30% re-
duction in serotonin in vivo synthesis rate in this and other [20, 183]
studies. However, this decrease resulted in little or no (ranging from
0 to 10 %) decrease in serotonin levels in different brain areas and
in the whole brain [20, 183, 194], whereby the small difference bet-
ween the studies in the serotonin content may arise from the time
of the day, and the food consumption and composition, which may
differ between the labs. However, extensive evaluation of behavioral
traits in these mouse strains revealed controversial results, such as a
lack of difference in anxiety- (EPM, MBT and NSF) and depression-
like behavior (TST [183], FST performed in this study and by others
[194]); lowered aggression, no differences in anxiety in the open field
test, and decreased immobility time in the FST [151]; elevated anxie-
ty (EPM, elevated zero maze, light-dark exploration test, and novel-
ty induced hypophagia), but no difference in the depression-like be-
havior at baseline and after chronic mild stress in TST, FST, sucrose
preference test, and learned helplessness [20]. This inconsistency in
behavior data obtained from congenic mice carrying the Tph21473G
allele on a pure genetic background could be partially due to dif-
ferent number of generations (3 to 8) the animals were backcrossed
[20, 151, 183]. It can also not be excluded that additional genetic traits
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may have been inherited with the Tph2 polymorphic allele during
the backcrossing by the different groups resulting in elevated anxie-
ty [20] or more pronounced depression-like behavior [62]. Moreover,
the observed discrepancy in the outcome of behavior testing could
lie in some small but essential methodological differences such as the
illumination used during anxiety tests, the housing conditions (group
and cage sizes, enrichment, lightning) and the testing conditions (for
example diameter and height of the beaker used in FST) [160].
This work has implications for human antidepressant therapy. SSRIs
and other measures which increase brain serotonin levels, such as
food supplementation with Trp, are widely used in humans for the
treatment of anxiety and depression-like disorders. Here I evaluated
the effect of such treatments on serotonin levels in brains of mice
with reduced TPH2 activity. Trp administration led to a substantial
elevation of brain serotonin levels in Tph2C/C , Tph2G/G , and Tph2C/-
Figure 27. However, in Tph2G/- mice it resulted only in a mild increase
in serotonin content, which remained clearly below the level of unt-
reated WT mice. Even more drastic differences between the mouse
strains were observed after the chronic treatment with the SSRI FLX
Table 11. While control animals showed a slight decrease in brain
serotonin levels in line with previous findings [7], this drop was much
more pronounced in mice with reduced TPH2 activity reaching a 60%
reduction in overall serotonin levels in Tph2G/- mice compared to un-
treated controls. Thus, the outcome of antidepressant therapy may be
dramatically affected in conditions of reduced TPH2 activity, leading
to inefficiency or possibly even to adverse effects of SSRIs.
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C O N C L U S I O N S
In the first part of this study I showed that serotonin is not required
for embryonic growth, but is crucial for postnatal development. Post-
natal growth retardation in central serotonin deficient mice was not
due to dysfunction of the hypothalamo-pituitary-adrenal axis, im-
paired thermoregulation, or improper food digestion but could origi-
nate from impaired pups’ ultrasonic vocalisation.
In the second part of this study I showed that a partial decrease in
brain serotonin has no influence on behavior while complete brain
serotonin ablation leads to strong behavioral consequences determined
by exaggerated aggression, increased depression-like beha- vior, and
decreased anxiety. In conditions of reduced serotonin production a
lowered serotonin degradation rate and 5-HT1A receptor sensitiza-
tion contribute to the maintenance of brain serotonin at le- vels which
are sufficient for adequate behavior responses.
Moreover, my data point out that the antidepressant fluoxetine may
implement at least part of its actions through serotonin-independent
mechanisms. Furthermore, fluoxetine treatment leads to a drastic re-
duction in serotonin levels in the brain in conditions of reduced TPH2
activity, which may negatively affect the outcome of antidepressant
therapy.
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A B B R E V I AT I O N S
5-HIAA — 5-hydroxyinole acetic acid
5-HT — serotonin
5-HTP — 5-hydroxytryptophan
A — amygdala
AADC — aromatic aminoacid decarboxylase
ADH — alcohol dehydrogenase
BDNF — brain-derived neurotrophic factor
BH4 — tetrahydrobiopterin
BrdU — bromodeoxyuridine
BS — brain stem
C — cortex
CNS — central nervous system
DA — dopamine
DOPAC — 3,4-dihydroxyphenylacetic acid
EPM — elevated plus maze
FC — frontal cortex
FLX — fluoxetine
FST — forced swim test
GABA — gamma-aminobutyric acid
GH — growth hormone
HFD — high fat diet
HIOMT — hydroxy-indole-O-methyl transferase
Hip — hippocampus
HPA — hypothalamo-pituitary-adrenal axis
HPLC — high-performance liquid chromatography
HVA — homovanillic acid
IGF — insulin-like growth factor
LSD — lysergic acid diethylamine
MAO — monoamine oxidase
MBT — marble burying test
MWM — Morris water maze
NA — noradrenaline
NE — norepinephrine
ND — normal diet
NM — normetanephrine
NSD — 3-hydroxybenzylhydrazine
NSF — novelty suppressed feeding
Ob — olfactory balb
OF — open field
PAH — phenylalanine hydroxylase
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abbreviations
PCPA — parachlorphenylalanine
PFA — paraformaldehyde
PVN — paraventricular nuclei
RI — resident intruder
RR — rostral raphe
SD — standard diet
SERT — selective serotonin transporter
SGZ — subgranular zone
SN — substancia nigra
SNAT — serotonin N-acetyltransferase
SNP — single nucleotide polymorphism
SSRI — selective serotonin transporter inhibitor
SST — somatostatin
T — thalamus
TBP — TATA box binding protein
TH — tyrosine hydroxylase
TPH — tryptophan hydroxylase
Trp — tryptophan
TST — tail suspension test
USV — ultrasonic vocalisation
VMAT — vesicular monoamine transporter
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